1574-Application-Redacted

Application Form: 1574Non-invasive prenatal testing for Rhesus DPART 1 – APPLICANT DETAILSApplicant details (primary and alternative contacts)Corporation / partnership details (where relevant): Corporation name: The Royal College of Pathologists of AustralasiaABN: 52 000 173 231Business trading name: The Royal College of Pathologists of AustralasiaPrimary contact name: Dr Debra GravesPrimary contact numbersBusiness: REDACTEDMobile: REDACTED Email: REDACTEDAlternative contact name: Ms Linda MundyAlternative contact numbersBusiness: REDACTEDMobile: REDACTEDEmail: REDACTED(a) Are you a lobbyist acting on behalf of an Applicant? FORMCHECKBOX Yes FORMCHECKBOX No If yes, are you listed on the Register of Lobbyists? FORMCHECKBOX Yes FORMCHECKBOX No PART 2 – INFORMATION ABOUT THE PROPOSED MEDICAL SERVICEApplication title Non-Invasive Prenatal Testing (NIPT) for fetal Rhesus D genotypeProvide a succinct description of the medical condition relevant to the proposed service (no more than 150 words – further information will be requested at Part F of the Application Form)Approximately one in seven women has a rhesus (Rh) D-negative blood group. RhD negative women carrying an RhD-positive fetus are at risk of becoming sensitised, producing antibodies against the RhD antigen if fetal cells enter the maternal circulation. Sensitisation places the RhD-positive fetus and future RhD-positive pregnancies at risk of haemolytic disease of the fetus and newborn (HDFN). If undiagnosed and/or untreated, HDFN carries significant risk of perinatal morbidity and mortality. ADDIN EN.CITE <EndNote><Cite><Author>Lyon</Author><Year>2018</Year><RecNum>49</RecNum><IDText>29726855</IDText><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533107858">49</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lyon, C.</author><author>English, A.</author></authors></contributors><auth-address>University of Colorado Family Medicine Residency Program, Denver, Colorado, USA.</auth-address><titles><title>PURL: A new protocol for RhD-negative pregnant women?</title><secondary-title>J Fam Pract</secondary-title></titles><periodical><full-title>J Fam Pract</full-title></periodical><pages>306;308;319</pages><volume>67</volume><number>5</number><edition>2018/05/05</edition><dates><year>2018</year><pub-dates><date>May</date></pub-dates></dates><isbn>1533-7294 (Electronic)0094-3509 (Linking)</isbn><accession-num>29726855</accession-num><urls><related-urls><url> In Australia, the current standard of care is the routine administration anti-D immunoglobulin to all RhD negative pregnant women at 28 and 34 weeks’ gestation, and within 72 hours of delivery of an RhD-positive fetus, or following other obstetric events associated with a risk of fetal-to-maternal haemorrhage. ADDIN EN.CITE <EndNote><Cite><Author>RANZCOG</Author><Year>2015</Year><RecNum>25</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533105490">25</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>RANZCOG</author></authors></contributors><titles><title>Guidelines for the use of Rh(D) Immunoglobulin (Anti-D) in obstetrics in Australia</title></titles><volume>2018</volume><number>1st August</number><dates><year>2015</year></dates><publisher>The Royal Australian and New Zealand College of Obstetricians and Gynaecologists</publisher><urls><related-urls><url> a succinct description of the proposed medical service (no more than 150 words – further information will be requested at Part 6 of the Application Form)Cell-free fetal DNA (cffDNA) present in the maternal circulation is detected by high-throughput non-invasive prenatal testing (HT-NIPT), using real-time quantitative polymerase chain reaction (PCR). HT-NIPT is used to determine the RhD genotype of a fetus carried by a RhD-negative woman by detecting the presence of cffDNA fragments in the mother’s plasma. The presence of RhD-positive cffDNA would indicate the presence of a RHD gene, which suggests a RhD-positive fetus. ADDIN EN.CITE <EndNote><Cite><Author>Saramago</Author><Year>2018</Year><RecNum>3</RecNum><IDText>29580376</IDText><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533100529">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Saramago, P.</author><author>Yang, H.</author><author>Llewellyn, A.</author><author>Walker, R.</author><author>Harden, M.</author><author>Palmer, S.</author><author>Griffin, S.</author><author>Simmonds, M.</author></authors></contributors><auth-address>Centre for Health Economics, University of York, York, UK.Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.Centre for Reviews and Dissemination, University of York, York, UK.</auth-address><titles><title>High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation</title><secondary-title>Health Technol Assess</secondary-title></titles><periodical><full-title>Health Technol Assess</full-title></periodical><pages>1-172</pages><volume>22</volume><number>13</number><edition>2018/03/28</edition><dates><year>2018</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>2046-4924 (Electronic)1366-5278 (Linking)</isbn><accession-num>29580376</accession-num><urls></urls><custom2>PMC5890172</custom2><electronic-resource-num>10.3310/hta22130</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>3(a) Is this a request for MBS funding? FORMCHECKBOX Yes FORMCHECKBOX No If yes, is the medical service(s) proposed to be covered under an existing MBS item number(s) or is a new MBS item(s) being sought altogether? FORMCHECKBOX Amendment to existing MBS item(s) FORMCHECKBOX New MBS item(s)If an amendment to an existing item(s) is being sought, please list the relevant MBS item number(s) that are to be amended to include the proposed medical service: N/AIf an amendment to an existing item(s) is being sought, what is the nature of the amendment(s)? FORMCHECKBOX An amendment to the way the service is clinically delivered under the existing item(s) FORMCHECKBOX An amendment to the patient population under the existing item(s) FORMCHECKBOX An amendment to the schedule fee of the existing item(s) FORMCHECKBOX An amendment to the time and complexity of an existing item(s) FORMCHECKBOX Access to an existing item(s) by a different health practitioner group FORMCHECKBOX Minor amendments to the item descriptor that does not affect how the service is delivered FORMCHECKBOX An amendment to an existing specific single consultation item FORMCHECKBOX An amendment to an existing global consultation item(s) FORMCHECKBOX Other (please describe below):N/AIf a new item(s) is being requested, what is the nature of the change to the MBS being sought? FORMCHECKBOX A new item which also seeks to allow access to the MBS for a specific health practitioner group FORMCHECKBOX A new item that is proposing a way of clinically delivering a service that is new to the MBS (in terms of new technology and / or population) FORMCHECKBOX A new item for a specific single consultation item FORMCHECKBOX A new item for a global consultation item(s)Is the proposed service seeking public funding other than the MBS? FORMCHECKBOX Yes FORMCHECKBOX NoIf yes, please advise:What is the type of service: FORMCHECKBOX Therapeutic medical service FORMCHECKBOX Investigative medical service FORMCHECKBOX Single consultation medical service FORMCHECKBOX Global consultation medical service FORMCHECKBOX Allied health service FORMCHECKBOX Co-dependent technology FORMCHECKBOX Hybrid health technologyFor investigative services, advise the specific purpose of performing the service (which could be one or more of the following): FORMCHECKBOX To be used as a screening tool in asymptomatic populations FORMCHECKBOX Assists in establishing a diagnosis in symptomatic patients FORMCHECKBOX Provides information about prognosis FORMCHECKBOX Identifies a patient as suitable for therapy by predicting a variation in the effect of the therapy FORMCHECKBOX Monitors a patient over time to assess treatment response and guide subsequent treatment decisions FORMCHECKBOX A service that tests for heritable mutations in clinically affected individuals to make a genetic diagnosis and thus estimate their variation in (predisposition for) future risk of further disease and, when also appropriate, cascade testing of family members of those individuals who test positive for one or more relevant mutations, to make a genetic diagnosis and thus estimate each family member’s variation in (predisposition for) future risk of developing the clinical disease.Does your service rely on another medical product to achieve or to enhance its intended effect? FORMCHECKBOX Pharmaceutical / Biological FORMCHECKBOX Prosthesis or device FORMCHECKBOX No(a) If the proposed service has a pharmaceutical component to it, is it already covered under an existing Pharmaceutical Benefits Scheme (PBS) listing? FORMCHECKBOX Yes FORMCHECKBOX No If yes, please list the relevant PBS item code(s):If no, is an application (submission) in the process of being considered by the Pharmaceutical Benefits Advisory Committee (PBAC)? FORMCHECKBOX Yes (please provide PBAC submission item number below) FORMCHECKBOX NoIf you are seeking both MBS and PBS listing, what is the trade name and generic name of the pharmaceutical?Trade name: Generic name: (a) If the proposed service is dependent on the use of a prosthesis, is it already included on the Prostheses List? FORMCHECKBOX Yes FORMCHECKBOX No N/AIf yes, please provide the following information (where relevant): Billing code(s): Trade name of prostheses: Clinical name of prostheses: Other device components delivered as part of the service: If no, is an application in the process of being considered by a Clinical Advisory Group or the Prostheses List Advisory Committee (PLAC)? FORMCHECKBOX Yes FORMCHECKBOX No Are there any other sponsor(s) and / or manufacturer(s) that have a similar prosthesis or device component in the Australian market place which this application is relevant to? FORMCHECKBOX Yes FORMCHECKBOX No If yes, please provide the name(s) of the sponsor(s) and / or manufacturer(s):Please identify any single and / or multi-use consumables delivered as part of the service?Single use consumables: Laboratory consumables used to conduct quantitative polymerase chain reaction, such as primers, reaction tubes and laboratory pipette tips. Multi-use consumables: NilPART 3 – INFORMATION ABOUT REGULATORY REQUIREMENTS(a) If the proposed medical service involves the use of a medical device, in-vitro diagnostic test, pharmaceutical product, radioactive tracer or any other type of therapeutic good, please provide the following details:Type of therapeutic good: In-vitro diagnostic test developed “in-house”Manufacturer’s name: N/ASponsor’s name: N/AIs the medical device classified by the TGA as either a Class III or Active Implantable Medical Device (AIMD) against the TGA regulatory scheme for devices? FORMCHECKBOX Class III FORMCHECKBOX AIMD FORMCHECKBOX N/A FORMCHECKBOX Class 4 in-house IVD(a) Is the therapeutic good to be used in the service exempt from the regulatory requirements of the Therapeutic Goods Act 1989? FORMCHECKBOX Yes (If yes, please provide supporting documentation as an attachment to this application form) FORMCHECKBOX NoIf no, has it been listed or registered or included in the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA)? FORMCHECKBOX Yes (if yes, please provide details below) FORMCHECKBOX NoARTG listing, registration or inclusion number: TGA approved indication(s), if applicable: TGA approved purpose(s), if applicable: If the therapeutic good has not been listed, registered or included in the ARTG, is the therapeutic good in the process of being considered for inclusion by the TGA? FORMCHECKBOX Yes (please provide details below) FORMCHECKBOX NoDate of submission to TGA: Estimated date by which TGA approval can be expected: TGA Application ID: TGA approved indication(s), if applicable: TGA approved purpose(s), if applicable: If the therapeutic good is not in the process of being considered for listing, registration or inclusion by the TGA, is an application to the TGA being prepared? FORMCHECKBOX Yes (please provide details below) FORMCHECKBOX NoEstimated date of submission to TGA: Proposed indication(s), if applicable: Proposed purpose(s), if applicable:PART 4 – SUMMARY OF EVIDENCEProvide an overview of all key journal articles or research published in the public domain related to the proposed service that is for your application (limiting these to the English language only). Please do not attach full text articles, this is just intended to be a summary.-Type of study design*Title of journal article or research project (including any trial identifier or study lead if relevant)Short description of research (max 50 words)**Website link to journal article or research (if available)Date of publication***1.Diagnostic accuracyDetermination of fetal RHD type in plasma of RhD negative pregnant women ADDIN EN.CITE <EndNote><Cite><Author>Sorensen</Author><Year>2018</Year><RecNum>51</RecNum><IDText>29869532</IDText><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534305406">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sorensen, K.</author><author>Kjeldsen-Kragh, J.</author><author>Husby, H.</author><author>Akkok, C. A.</author></authors></contributors><auth-address>a Department of Immunology and Transfusion Medicine , Oslo University Hospital , Oslo , Norway.b Department of Clinical Immunology and Transfusion Medicine , University and Regional Laboratories Region Skane , Lund , Sweden.c Department of Obstetrics , Oslo University Hospital , Oslo , Norway.</auth-address><titles><title>Determination of fetal RHD type in plasma of RhD negative pregnant women</title><secondary-title>Scand J Clin Lab Invest</secondary-title></titles><periodical><full-title>Scand J Clin Lab Invest</full-title></periodical><pages>1-6</pages><edition>2018/06/06</edition><keywords><keyword>Dna</keyword><keyword>RHO(D) antibody</keyword><keyword>Rho(D) Immune Globulin</keyword><keyword>blood typing</keyword><keyword>fetus</keyword><keyword>genotyping</keyword><keyword>immunization</keyword><keyword>newborn</keyword><keyword>pregnancy</keyword><keyword>prenatal diagnosis/methods</keyword><keyword>real-time polymerase chain reaction</keyword></keywords><dates><year>2018</year><pub-dates><date>Jun 5</date></pub-dates></dates><isbn>1502-7686 (Electronic)0036-5513 (Linking)</isbn><accession-num>29869532</accession-num><urls><related-urls><url> fetal RHD genotype was studied in 373 samples from RhD negative pregnant women (median gestational week 24). DNA extracted from plasma was analysed for the presence/absence of RHD exon 7 and 10 in a real-time PCR. The RHD genotype of the fetus was compared with the serological RhD type of the newborn. In 234 samples, the fetal RHD test was positive and in 127 samples negative. There was one false positive and no false negative results. In 12 samples, the fetal RHD type could not be determined, in all of them due to a maternal RHD gene. review and economic evaluationHigh-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. ADDIN EN.CITE <EndNote><Cite><Author>Saramago</Author><Year>2018</Year><RecNum>3</RecNum><IDText>29580376</IDText><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533100529">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Saramago, P.</author><author>Yang, H.</author><author>Llewellyn, A.</author><author>Walker, R.</author><author>Harden, M.</author><author>Palmer, S.</author><author>Griffin, S.</author><author>Simmonds, M.</author></authors></contributors><auth-address>Centre for Health Economics, University of York, York, UK.Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.Centre for Reviews and Dissemination, University of York, York, UK.</auth-address><titles><title>High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation</title><secondary-title>Health Technol Assess</secondary-title></titles><periodical><full-title>Health Technol Assess</full-title></periodical><pages>1-172</pages><volume>22</volume><number>13</number><edition>2018/03/28</edition><dates><year>2018</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>2046-4924 (Electronic)1366-5278 (Linking)</isbn><accession-num>29580376</accession-num><urls></urls><custom2>PMC5890172</custom2><electronic-resource-num>10.3310/hta22130</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>3A systematic review of the evidence on the diagnostic accuracy, clinical effectiveness and implementation of high-throughput NIPT and the development of a cost-effectiveness model from the UK perspective. 8 studies were included in the diagnostic accuracy review, 7 studies were included in the clinical effectiveness review and 12 studies were included in the review of implementation. analysisHigh-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. ADDIN EN.CITE <EndNote><Cite><Author>Saramago</Author><Year>2018</Year><RecNum>22</RecNum><IDText>29415334</IDText><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533103978">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Saramago, P.</author><author>Yang, H.</author><author>Llewellyn, A.</author><author>Palmer, S.</author><author>Simmonds, M.</author><author>Griffin, S.</author></authors></contributors><auth-address>Centre for Health Economics, University of York, York, UK.Medical School, University of Exeter, Exeter, UK.Centre for Reviews and Dissemination, University of York, York, UK.</auth-address><titles><title>High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis</title><secondary-title>BJOG</secondary-title></titles><periodical><full-title>BJOG</full-title></periodical><edition>2018/02/08</edition><keywords><keyword>Cell-free fetal DNA</keyword><keyword>cost-effectiveness analysis</keyword><keyword>economic evaluation</keyword><keyword>non-invasive prenatal screening</keyword><keyword>rhesus</keyword></keywords><dates><year>2018</year><pub-dates><date>Feb 7</date></pub-dates></dates><isbn>1471-0528 (Electronic)1470-0328 (Linking)</isbn><accession-num>29415334</accession-num><urls><related-urls><url> decision tree model was used to characterise the antenatal care pathway in England and the long-term consequences of sensitisation events. Five alternative strategies in which the use of HT-NIPT may affect the existing postpartum care pathway were considered. The diagnostic accuracy of HT-NIPT was derived from the systematic review above. accuracyPrenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5mcm9pPC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48

UmVjTnVtPjYxPC9SZWNOdW0+PElEVGV4dD4yOTc1NzEzODwvSURUZXh0PjxEaXNwbGF5VGV4dD48

c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjY8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj42MTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9InJwdjIwYWRhZTl0c2Q2ZWFzMGRwOTBzd3hkdHYwYTI5czIwcyIgdGltZXN0YW1wPSIxNTM0

ODMwMTMzIj42MTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFy

dGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWFuZnJv

aSwgUy48L2F1dGhvcj48YXV0aG9yPkNhbGlzZXNpLCBDLjwvYXV0aG9yPjxhdXRob3I+RmFnaWFu

aSwgUC48L2F1dGhvcj48YXV0aG9yPkdhYnJpZWxlLCBBLjwvYXV0aG9yPjxhdXRob3I+TG9kaSwg

Ry48L2F1dGhvcj48YXV0aG9yPk51Y2NpLCBTLjwvYXV0aG9yPjxhdXRob3I+UGVsbGljb25pLCBT

LjwvYXV0aG9yPjxhdXRob3I+UmlnaGluaSwgTC48L2F1dGhvcj48YXV0aG9yPlJhbmRpLCBWLjwv

YXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkltbXVub2hhZW1h

dG9sb2d5IGFuZCBUcmFuc2Z1c2lvbiBNZWRpY2luZSBTZXJ2aWNlIE1ldHJvcG9saXRhbiBBcmVh

IG9mIEJvbG9nbmEsICZxdW90O1MuIE9yc29sYS1NYWxwaWdoaSZxdW90OyBQb2x5Y2xpbmljLCBC

b2xvZ25hLCBJdGFseS4mI3hEO0ltbXVub2hhZW1hdG9sb2d5IGFuZCBUcmFuc2Z1c2lvbiBNZWRp

Y2luZSBTZXJ2aWNlLCAmcXVvdDtPc3BlZGFsZSBkZWdsaSBJbmZlcm1pJnF1b3Q7LCBSaW1pbmks

IEl0YWx5LiYjeEQ7SW1tdW5vaGFlbWF0b2xvZ3kgYW5kIFRyYW5zZnVzaW9uIE1lZGljaW5lIFNl

cnZpY2UgTWV0cm9wb2xpdGFuIEFyZWEgb2YgQm9sb2duYSwgSW1vbGEgSG9zcGl0YWwsIEltb2xh

LCBJdGFseS4mI3hEO0ltbXVub2hhZW1hdG9sb2d5IGFuZCBUcmFuc2Z1c2lvbiBNZWRpY2luZSBT

ZXJ2aWNlIE1ldHJvcG9saXRhbiBBcmVhIG9mIEJvbG9nbmEsICZxdW90O01hZ2dpb3JlJnF1b3Q7

IEhvc3BpdGFsLCBCb2xvZ25hLCBJdGFseS4mI3hEO0ltbXVub2hhZW1hdG9sb2d5IGFuZCBUcmFu

c2Z1c2lvbiBNZWRpY2luZSBTZXJ2aWNlLCAmcXVvdDtTLiBBbm5hJnF1b3Q7IEhvc3BpdGFsLCBG

ZXJyYXJhLCBJdGFseS4mI3hEO1JlZ2lvbmFsIEJsb29kIENlbnRyZSBvZiBFbWlsaWEtUm9tYWdu

YSwgJnF1b3Q7TWFnZ2lvcmUmcXVvdDsgSG9zcGl0YWwsIEJvbG9nbmEsIEl0YWx5LjwvYXV0aC1h

ZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlByZW5hdGFsIG5vbi1pbnZhc2l2ZSBmb2V0YWwgUkhEIGdl

bm90eXBpbmc6IGRpYWdub3N0aWMgYWNjdXJhY3kgb2YgYSB0ZXN0IGFzIGEgZ3VpZGUgZm9yIGFw

cHJvcHJpYXRlIGFkbWluaXN0cmF0aW9uIG9mIGFudGVuYXRhbCBhbnRpLUQgaW1tdW5vcHJvcGh5

bGF4aXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+Qmxvb2QgVHJhbnNmdXM8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CbG9vZCBUcmFuc2Z1czwvZnVs

bC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEtMTE8L3BhZ2VzPjxlZGl0aW9uPjIwMTgvMDUv

MTU8L2VkaXRpb24+PGRhdGVzPjx5ZWFyPjIwMTg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BcHIg

OTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE3MjMtMjAwNyAoUHJpbnQpJiN4RDsx

NzIzLTIwMDcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI5NzU3MTM4PC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMjQ1MC8yMDE4

LjAyNzAtMTc8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlk

ZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+

PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5mcm9pPC9BdXRob3I+PFllYXI+MjAxODwvWWVhcj48

UmVjTnVtPjYxPC9SZWNOdW0+PElEVGV4dD4yOTc1NzEzODwvSURUZXh0PjxEaXNwbGF5VGV4dD48

c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjY8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj42MTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9InJwdjIwYWRhZTl0c2Q2ZWFzMGRwOTBzd3hkdHYwYTI5czIwcyIgdGltZXN0YW1wPSIxNTM0

ODMwMTMzIj42MTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFy

dGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWFuZnJv

aSwgUy48L2F1dGhvcj48YXV0aG9yPkNhbGlzZXNpLCBDLjwvYXV0aG9yPjxhdXRob3I+RmFnaWFu

aSwgUC48L2F1dGhvcj48YXV0aG9yPkdhYnJpZWxlLCBBLjwvYXV0aG9yPjxhdXRob3I+TG9kaSwg

Ry48L2F1dGhvcj48YXV0aG9yPk51Y2NpLCBTLjwvYXV0aG9yPjxhdXRob3I+UGVsbGljb25pLCBT

LjwvYXV0aG9yPjxhdXRob3I+UmlnaGluaSwgTC48L2F1dGhvcj48YXV0aG9yPlJhbmRpLCBWLjwv

YXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkltbXVub2hhZW1h

dG9sb2d5IGFuZCBUcmFuc2Z1c2lvbiBNZWRpY2luZSBTZXJ2aWNlIE1ldHJvcG9saXRhbiBBcmVh

IG9mIEJvbG9nbmEsICZxdW90O1MuIE9yc29sYS1NYWxwaWdoaSZxdW90OyBQb2x5Y2xpbmljLCBC

b2xvZ25hLCBJdGFseS4mI3hEO0ltbXVub2hhZW1hdG9sb2d5IGFuZCBUcmFuc2Z1c2lvbiBNZWRp

Y2luZSBTZXJ2aWNlLCAmcXVvdDtPc3BlZGFsZSBkZWdsaSBJbmZlcm1pJnF1b3Q7LCBSaW1pbmks

IEl0YWx5LiYjeEQ7SW1tdW5vaGFlbWF0b2xvZ3kgYW5kIFRyYW5zZnVzaW9uIE1lZGljaW5lIFNl

cnZpY2UgTWV0cm9wb2xpdGFuIEFyZWEgb2YgQm9sb2duYSwgSW1vbGEgSG9zcGl0YWwsIEltb2xh

LCBJdGFseS4mI3hEO0ltbXVub2hhZW1hdG9sb2d5IGFuZCBUcmFuc2Z1c2lvbiBNZWRpY2luZSBT

ZXJ2aWNlIE1ldHJvcG9saXRhbiBBcmVhIG9mIEJvbG9nbmEsICZxdW90O01hZ2dpb3JlJnF1b3Q7

IEhvc3BpdGFsLCBCb2xvZ25hLCBJdGFseS4mI3hEO0ltbXVub2hhZW1hdG9sb2d5IGFuZCBUcmFu

c2Z1c2lvbiBNZWRpY2luZSBTZXJ2aWNlLCAmcXVvdDtTLiBBbm5hJnF1b3Q7IEhvc3BpdGFsLCBG

ZXJyYXJhLCBJdGFseS4mI3hEO1JlZ2lvbmFsIEJsb29kIENlbnRyZSBvZiBFbWlsaWEtUm9tYWdu

YSwgJnF1b3Q7TWFnZ2lvcmUmcXVvdDsgSG9zcGl0YWwsIEJvbG9nbmEsIEl0YWx5LjwvYXV0aC1h

ZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlByZW5hdGFsIG5vbi1pbnZhc2l2ZSBmb2V0YWwgUkhEIGdl

bm90eXBpbmc6IGRpYWdub3N0aWMgYWNjdXJhY3kgb2YgYSB0ZXN0IGFzIGEgZ3VpZGUgZm9yIGFw

cHJvcHJpYXRlIGFkbWluaXN0cmF0aW9uIG9mIGFudGVuYXRhbCBhbnRpLUQgaW1tdW5vcHJvcGh5

bGF4aXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+Qmxvb2QgVHJhbnNmdXM8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CbG9vZCBUcmFuc2Z1czwvZnVs

bC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEtMTE8L3BhZ2VzPjxlZGl0aW9uPjIwMTgvMDUv

MTU8L2VkaXRpb24+PGRhdGVzPjx5ZWFyPjIwMTg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BcHIg

OTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE3MjMtMjAwNyAoUHJpbnQpJiN4RDsx

NzIzLTIwMDcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI5NzU3MTM4PC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMjQ1MC8yMDE4

LjAyNzAtMTc8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlk

ZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+

PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 6Cell-free foetal DNA was extracted from plasma of RhD-negative women between 11-30 weeks of pregnancy. The fetal RHD genotype was determined non-invasively by qPCR amplification of exons 5, 7 and 10 of the RHD gene. Results were compared with serological RhD cord blood typing at birth. The analysis of diagnostic accuracy was restricted to the period (24-28+6 weeks) during which fetal genotyping is usually performed for targeted antenatal immunoprophylaxis. Fetal RHD status was inconclusive in 9/284 samples, including 4 cases with RhD maternal variants. 2 false-positive results one false-negative result (in a sample collected at 18 weeks) were registered. After inclusion of samples at early gestational age (<23 week), sensitivity and accuracy were 99.6% and 95.5%, respectively. accuracyNon-invasive foetal RhD genotyping to guide anti-D prophylaxis: an external quality assurance workshop ADDIN EN.CITE <EndNote><Cite><Author>Clausen</Author><Year>2018</Year><RecNum>57</RecNum><IDText>28488977</IDText><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534830133">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Clausen, F. B.</author><author>Barrett, A. N.</author><author>Krog, G. R.</author><author>Finning, K.</author><author>Dziegiel, M. H.</author></authors></contributors><auth-address>Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom.</auth-address><titles><title>Non-invasive foetal RhD genotyping to guide anti-D prophylaxis: an external quality assurance workshop</title><secondary-title>Blood Transfus</secondary-title></titles><periodical><full-title>Blood Transfus</full-title></periodical><pages>359-362</pages><volume>16</volume><number>4</number><edition>2017/05/11</edition><dates><year>2018</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>1723-2007 (Print)1723-2007 (Linking)</isbn><accession-num>28488977</accession-num><urls><related-urls><url> external quality assurance workshop in which 22 laboratories (including ones in Australia) participated in testing two plasma samples from pregnant RhD-negative women, with the aim of future development of standards for testing for foetal RhD genotype. review and bivariate meta-analysisThe accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis ADDIN EN.CITE <EndNote><Cite><Author>Mackie</Author><Year>2017</Year><RecNum>48</RecNum><IDText>27245374</IDText><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533107703">48</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mackie, F. L.</author><author>Hemming, K.</author><author>Allen, S.</author><author>Morris, R. K.</author><author>Kilby, M. D.</author></authors></contributors><auth-address>Centre for Women's & Newborn Health and the Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.Public Health, Epidemiology and Biostatistics, Institute of Applied Health Sciences, University of Birmingham, Birmingham, UK.West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital NHS Foundation Trust, Birmingham, UK.Fetal Medicine Centre, Birmingham Women's Hospital NHS Foundation Trust, Birmingham, UK.</auth-address><titles><title>The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis</title><secondary-title>BJOG</secondary-title></titles><periodical><full-title>BJOG</full-title></periodical><pages>32-46</pages><volume>124</volume><number>1</number><edition>2016/06/02</edition><keywords><keyword>Cell-free fetal DNA</keyword><keyword>diagnostic accuracy</keyword><keyword>non-invasive prenatal testing</keyword></keywords><dates><year>2017</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1471-0528 (Electronic)1470-0328 (Linking)</isbn><accession-num>27245374</accession-num><urls><related-urls><url> accuracy of cffDNA-based NIPT for all conditions and to evaluate the influence of other factors on test performance. Included cohort studies reporting cffDNA-based NIPT performance in singleton pregnancies. For fetal rhesus D status, NIPT can be considered diagnostic. Bivariate meta-analysis demonstrated sensitivities and specificities, respectively for rhesus D, 0.993 (95% CI 0.982–0.997) and 0.984 (95% CI 0.964–0.993), 10 290 tests. cohortTargeted antenatal anti-D prophylaxis program for RhD-negative pregnant women – outcome of the first two years of a national program in FinlandPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWltaWxhPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48

UmVjTnVtPjE5PC9SZWNOdW0+PElEVGV4dD4yODcxODE5ODwvSURUZXh0PjxEaXNwbGF5VGV4dD48

c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjk8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj4xOTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9InJwdjIwYWRhZTl0c2Q2ZWFzMGRwOTBzd3hkdHYwYTI5czIwcyIgdGltZXN0YW1wPSIxNTMz

MTAxNDI0Ij4xOTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFy

dGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SGFpbWls

YSwgSy48L2F1dGhvcj48YXV0aG9yPlN1bGluLCBLLjwvYXV0aG9yPjxhdXRob3I+S3Vvc21hbmVu

LCBNLjwvYXV0aG9yPjxhdXRob3I+U2FyZW5ldmEsIEkuPC9hdXRob3I+PGF1dGhvcj5Lb3Job25l

biwgQS48L2F1dGhvcj48YXV0aG9yPk5hdHVuZW4sIFMuPC9hdXRob3I+PGF1dGhvcj5UdWltYWxh

LCBKLjwvYXV0aG9yPjxhdXRob3I+U2FpbmlvLCBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPkZpbm5pc2ggUmVkIENyb3NzIEJsb29kIFNlcnZpY2UsIEhl

bHNpbmtpLCBGaW5sYW5kLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRhcmdldGVkIGFu

dGVuYXRhbCBhbnRpLUQgcHJvcGh5bGF4aXMgcHJvZ3JhbSBmb3IgUmhELW5lZ2F0aXZlIHByZWdu

YW50IHdvbWVuIC0gb3V0Y29tZSBvZiB0aGUgZmlyc3QgdHdvIHllYXJzIG9mIGEgbmF0aW9uYWwg

cHJvZ3JhbSBpbiBGaW5sYW5kPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFjdGEgT2JzdGV0IEd5

bmVjb2wgU2NhbmQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10

aXRsZT5BY3RhIE9ic3RldCBHeW5lY29sIFNjYW5kPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48

cGFnZXM+MTIyOC0xMjMzPC9wYWdlcz48dm9sdW1lPjk2PC92b2x1bWU+PG51bWJlcj4xMDwvbnVt

YmVyPjxlZGl0aW9uPjIwMTcvMDcvMTk8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkNvbmZp

ZGVuY2UgSW50ZXJ2YWxzPC9rZXl3b3JkPjxrZXl3b3JkPkRpYWdub3N0aWMgVGVzdHMsIFJvdXRp

bmUvc3RhdGlzdGljcyAmYW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29yZD5GZW1h

bGU8L2tleXdvcmQ+PGtleXdvcmQ+RmlubGFuZDwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tl

eXdvcmQ+PGtleXdvcmQ+TmF0aW9uYWwgSGVhbHRoIFByb2dyYW1zPC9rZXl3b3JkPjxrZXl3b3Jk

Pk9kZHMgUmF0aW88L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3Jk

PlByZWduYW5jeSBDb21wbGljYXRpb25zLCBIZW1hdG9sb2dpYy9ibG9vZC9wcmV2ZW50aW9uICZh

bXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+UHJlbmF0YWwgRGlhZ25vc2lzLyBtZXRob2Rz

PC9rZXl3b3JkPjxrZXl3b3JkPlJoIElzb2ltbXVuaXphdGlvbi8gZGlhZ25vc2lzLyBwcmV2ZW50

aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+UmgtSHIgQmxvb2QtR3JvdXAgU3lz

dGVtL2Jsb29kPC9rZXl3b3JkPjxrZXl3b3JkPlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGJsb29k

PC9rZXl3b3JkPjxrZXl3b3JkPlJoZDwva2V5d29yZD48a2V5d29yZD5hbnRpLUQgcHJvcGh5bGF4

aXM8L2tleXdvcmQ+PGtleXdvcmQ+ZmV0YWwgY2VsbC1mcmVlIEROQTwva2V5d29yZD48a2V5d29y

ZD5oZW1vbHl0aWMgZGlzZWFzZSBvZiB0aGUgZmV0dXMgYW5kIG5ld2Jvcm48L2tleXdvcmQ+PGtl

eXdvcmQ+aW1tdW5pemF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPm5vbi1pbnZhc2l2ZSB0ZXN0aW5n

PC9rZXl3b3JkPjxrZXl3b3JkPnJvdXRpbmUgYW50ZW5hdGFsIGFudGktRCBwcm9waHlsYXhpczwv

a2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE3PC95ZWFyPjxwdWItZGF0ZXM+PGRh

dGU+T2N0PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTYwMC0wNDEyIChFbGVjdHJv

bmljKSYjeEQ7MDAwMS02MzQ5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yODcxODE5

ODwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly9vYmd5bi5v

bmxpbmVsaWJyYXJ5LndpbGV5LmNvbS9kb2kvcGRmLzEwLjExMTEvYW9ncy4xMzE5MTwvdXJsPjwv

cmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTExMS9hb2dz

LjEzMTkxPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVy

Pk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwv

cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWltaWxhPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48

UmVjTnVtPjE5PC9SZWNOdW0+PElEVGV4dD4yODcxODE5ODwvSURUZXh0PjxEaXNwbGF5VGV4dD48

c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjk8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj4xOTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9InJwdjIwYWRhZTl0c2Q2ZWFzMGRwOTBzd3hkdHYwYTI5czIwcyIgdGltZXN0YW1wPSIxNTMz

MTAxNDI0Ij4xOTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFy

dGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SGFpbWls

YSwgSy48L2F1dGhvcj48YXV0aG9yPlN1bGluLCBLLjwvYXV0aG9yPjxhdXRob3I+S3Vvc21hbmVu

LCBNLjwvYXV0aG9yPjxhdXRob3I+U2FyZW5ldmEsIEkuPC9hdXRob3I+PGF1dGhvcj5Lb3Job25l

biwgQS48L2F1dGhvcj48YXV0aG9yPk5hdHVuZW4sIFMuPC9hdXRob3I+PGF1dGhvcj5UdWltYWxh

LCBKLjwvYXV0aG9yPjxhdXRob3I+U2FpbmlvLCBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPkZpbm5pc2ggUmVkIENyb3NzIEJsb29kIFNlcnZpY2UsIEhl

bHNpbmtpLCBGaW5sYW5kLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRhcmdldGVkIGFu

dGVuYXRhbCBhbnRpLUQgcHJvcGh5bGF4aXMgcHJvZ3JhbSBmb3IgUmhELW5lZ2F0aXZlIHByZWdu

YW50IHdvbWVuIC0gb3V0Y29tZSBvZiB0aGUgZmlyc3QgdHdvIHllYXJzIG9mIGEgbmF0aW9uYWwg

cHJvZ3JhbSBpbiBGaW5sYW5kPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFjdGEgT2JzdGV0IEd5

bmVjb2wgU2NhbmQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10

aXRsZT5BY3RhIE9ic3RldCBHeW5lY29sIFNjYW5kPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48

cGFnZXM+MTIyOC0xMjMzPC9wYWdlcz48dm9sdW1lPjk2PC92b2x1bWU+PG51bWJlcj4xMDwvbnVt

YmVyPjxlZGl0aW9uPjIwMTcvMDcvMTk8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkNvbmZp

ZGVuY2UgSW50ZXJ2YWxzPC9rZXl3b3JkPjxrZXl3b3JkPkRpYWdub3N0aWMgVGVzdHMsIFJvdXRp

bmUvc3RhdGlzdGljcyAmYW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29yZD5GZW1h

bGU8L2tleXdvcmQ+PGtleXdvcmQ+RmlubGFuZDwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tl

eXdvcmQ+PGtleXdvcmQ+TmF0aW9uYWwgSGVhbHRoIFByb2dyYW1zPC9rZXl3b3JkPjxrZXl3b3Jk

Pk9kZHMgUmF0aW88L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3Jk

PlByZWduYW5jeSBDb21wbGljYXRpb25zLCBIZW1hdG9sb2dpYy9ibG9vZC9wcmV2ZW50aW9uICZh

bXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+UHJlbmF0YWwgRGlhZ25vc2lzLyBtZXRob2Rz

PC9rZXl3b3JkPjxrZXl3b3JkPlJoIElzb2ltbXVuaXphdGlvbi8gZGlhZ25vc2lzLyBwcmV2ZW50

aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+UmgtSHIgQmxvb2QtR3JvdXAgU3lz

dGVtL2Jsb29kPC9rZXl3b3JkPjxrZXl3b3JkPlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGJsb29k

PC9rZXl3b3JkPjxrZXl3b3JkPlJoZDwva2V5d29yZD48a2V5d29yZD5hbnRpLUQgcHJvcGh5bGF4

aXM8L2tleXdvcmQ+PGtleXdvcmQ+ZmV0YWwgY2VsbC1mcmVlIEROQTwva2V5d29yZD48a2V5d29y

ZD5oZW1vbHl0aWMgZGlzZWFzZSBvZiB0aGUgZmV0dXMgYW5kIG5ld2Jvcm48L2tleXdvcmQ+PGtl

eXdvcmQ+aW1tdW5pemF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPm5vbi1pbnZhc2l2ZSB0ZXN0aW5n

PC9rZXl3b3JkPjxrZXl3b3JkPnJvdXRpbmUgYW50ZW5hdGFsIGFudGktRCBwcm9waHlsYXhpczwv

a2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE3PC95ZWFyPjxwdWItZGF0ZXM+PGRh

dGU+T2N0PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTYwMC0wNDEyIChFbGVjdHJv

bmljKSYjeEQ7MDAwMS02MzQ5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yODcxODE5

ODwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly9vYmd5bi5v

bmxpbmVsaWJyYXJ5LndpbGV5LmNvbS9kb2kvcGRmLzEwLjExMTEvYW9ncy4xMzE5MTwvdXJsPjwv

cmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTExMS9hb2dz

LjEzMTkxPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVy

Pk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwv

cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA 9The aim of this study was to assess the accuracy of the non-invasive fetal RHD test at 24–26 weeks of gestation as part of the national Finnish antenatal screening program to target routine antenatal anti-D prophylaxis at 28–30 weeks for women carrying an RhD-positive fetus. A prospective cohort study involving all maternity care centres and delivery hospitals in Finland between February 2014 and January 2016. Fetal RHD genotyping using cell-free fetal DNA in maternal plasma was performed with real-time PCR with results compared with the serological newborn RhD typing. Fetal RHD was screened from 10,814 women. For the detection of fetal RHD, sensitivity was 99.99% and specificity 99.81%. One false-negative and 7 false-positive results were reported by the delivery hospitals in two years. The negative predictive value of the test was 99.97%. At the end of the study period, over 98% of the RhD-negative women participated in the new screening program. analysisNoninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti‐D therapy in Australia: A cost‐effectiveness analysis ADDIN EN.CITE <EndNote><Cite><Author>Gordon</Author><Year>2017</Year><RecNum>15</RecNum><IDText>29096422</IDText><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533101424">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gordon, L. G.</author><author>Hyland, C. A.</author><author>Hyett, J. A.</author><author>O'Brien, H.</author><author>Millard, G.</author><author>Flower, R. L.</author><author>Gardener, G. J.</author></authors></contributors><auth-address>QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Australia.Queensland University of Technology, School of Nursing, Brisbane, Australia.Australian Red Cross Blood Service, Brisbane, Australia.Clinical Professor and Head of High Risk Obstetrics, RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, Australia.Centre for Maternal Fetal Medicine at Mater Mothers' Hospitals, Brisbane, Australia.</auth-address><titles><title>Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis</title><secondary-title>Prenat Diagn</secondary-title></titles><periodical><full-title>Prenat Diagn</full-title></periodical><pages>1245-1253</pages><volume>37</volume><number>12</number><edition>2017/11/03</edition><dates><year>2017</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1097-0223 (Electronic)0197-3851 (Linking)</isbn><accession-num>29096422</accession-num><urls><related-urls><url> decision‐analytic model was constructed to compare RHD testing and targeted anti‐D prophylaxis, with current universal anti‐D prophylaxis among pregnant women with RhD negative blood type. cohort, diagnostic accuracyDiagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancyPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WaXZhbnRpPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjM3PC9SZWNOdW0+PElEVGV4dD4yNzM5MzI3MTwvSURUZXh0PjxEaXNwbGF5VGV4dD48

c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjExPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+Mzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSJycHYyMGFkYWU5dHNkNmVhczBkcDkwc3d4ZHR2MGEyOXMyMHMiIHRpbWVzdGFtcD0iMTUz

MzEwNjczNiI+Mzc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlZpdmFu

dGksIEEuPC9hdXRob3I+PGF1dGhvcj5CZW5hY2hpLCBBLjwvYXV0aG9yPjxhdXRob3I+SHVjaGV0

LCBGLiBYLjwvYXV0aG9yPjxhdXRob3I+VmlsbGUsIFkuPC9hdXRob3I+PGF1dGhvcj5Db2hlbiwg

SC48L2F1dGhvcj48YXV0aG9yPkNvc3RhLCBKLiBNLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPlNlcnZpY2UgZGUgR3luZWNvbG9naWUtT2JzdGV0cmlxdWUg

ZXQgTWVkZWNpbmUgZGUgbGEgUmVwcm9kdWN0aW9uLCBIb3BpdGFsIEFudG9pbmUgQmVjbGVyZSwg

VW5pdmVyc2l0ZSBQYXJpcyBTdWQsIENsYW1hcnQsIEZyYW5jZS4mI3hEO0xhYm9yYXRvaXJlIGRl

IEJpb2xvZ2llIE1lZGljYWxlLCBQYXJpcywgRnJhbmNlLiYjeEQ7U2VydmljZSBkZSBHeW5lY29s

b2dpZS1PYnN0ZXRyaXF1ZSwgSG9waXRhbCBOZWNrZXItRW5mYW50cyBNYWxhZGVzLCBQYXJpcywg

RnJhbmNlLiYjeEQ7RGVwYXJ0ZW1lbnQgTWVyZS1FbmZhbnQsIEluc3RpdHV0IE1vbnRzb3VyaXMs

IFBhcmlzLCBGcmFuY2UuJiN4RDtEZXBhcnRlbWVudCBkZSBCaW9sb2dpZSBTcGVjaWFsaXNlZSBl

dCBkZSBHZW5ldGlxdWUsIExhYm9yYXRvaXJlIENFUkJBLCBTYWludC1PdWVuIGwmYXBvcztBdW1v

bmUsIEZyYW5jZS4gRWxlY3Ryb25pYyBhZGRyZXNzOiBqbWNvc3RhQGxhYi1jZXJiYS5jb20uPC9h

dXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RGlhZ25vc3RpYyBhY2N1cmFjeSBvZiBmZXRhbCBy

aGVzdXMgRCBnZW5vdHlwaW5nIHVzaW5nIGNlbGwtZnJlZSBmZXRhbCBETkEgZHVyaW5nIHRoZSBm

aXJzdCB0cmltZXN0ZXIgb2YgcHJlZ25hbmN5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFtIEog

T2JzdGV0IEd5bmVjb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5BbSBKIE9ic3RldCBHeW5lY29sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn

ZXM+NjA2IGUxLTYwNiBlNTwvcGFnZXM+PHZvbHVtZT4yMTU8L3ZvbHVtZT48bnVtYmVyPjU8L251

bWJlcj48ZWRpdGlvbj4yMDE2LzEwLzMwPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVs

dDwva2V5d29yZD48a2V5d29yZD5CbG9vZCBHcm91cCBJbmNvbXBhdGliaWxpdHkvIGRpYWdub3Np

cy9kcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RE5BLyBibG9vZDwva2V5d29yZD48a2V5

d29yZD5FeG9uczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+RmV0

dXMvIG1ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+R2Vub3R5cGluZyBUZWNobmlxdWVzPC9r

ZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdv

cmQ+PGtleXdvcmQ+UHJlZ25hbmN5IFRyaW1lc3RlciwgRmlyc3Q8L2tleXdvcmQ+PGtleXdvcmQ+

UmVhbC1UaW1lIFBvbHltZXJhc2UgQ2hhaW4gUmVhY3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+UmV0

cm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdyb3VwIFN5

c3RlbS8gZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+UmhvKEQpIEltbXVuZSBHbG9idWxpbi90

aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+U2Vuc2l0aXZpdHkgYW5kIFNwZWNpZmlj

aXR5PC9rZXl3b3JkPjxrZXl3b3JkPlJIRCBnZW5vdHlwaW5nPC9rZXl3b3JkPjxrZXl3b3JkPmNl

bGwtZnJlZSBmZXRhbCBETkE8L2tleXdvcmQ+PGtleXdvcmQ+bWF0ZXJuYWwgc2VydW08L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk5v

djwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjEwOTctNjg2OCAoRWxlY3Ryb25pYykm

I3hEOzAwMDItOTM3OCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjczOTMyNzE8L2Fj

Y2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vYWMuZWxzLWNkbi5j

b20vUzAwMDI5Mzc4MTYzMDM5OTQvMS1zMi4wLVMwMDAyOTM3ODE2MzAzOTk0LW1haW4ucGRmP190

aWQ9ZGY1YmI0YjUtN2RiYS00NmY0LWI1OTEtYmY1ZWQ3MmEwOTJjJmFtcDthY2RuYXQ9MTUzMzEw

Njk3NF81ODU0MzhjZTZjYmYwOWEyODA1N2NhYzg3YTkxOGQzZjwvdXJsPjwvcmVsYXRlZC11cmxz

PjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9qLmFqb2cuMjAxNi4wNi4w

NTQ8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxN

PC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNv

cmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WaXZhbnRpPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjM3PC9SZWNOdW0+PElEVGV4dD4yNzM5MzI3MTwvSURUZXh0PjxEaXNwbGF5VGV4dD48

c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjExPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+Mzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSJycHYyMGFkYWU5dHNkNmVhczBkcDkwc3d4ZHR2MGEyOXMyMHMiIHRpbWVzdGFtcD0iMTUz

MzEwNjczNiI+Mzc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlZpdmFu

dGksIEEuPC9hdXRob3I+PGF1dGhvcj5CZW5hY2hpLCBBLjwvYXV0aG9yPjxhdXRob3I+SHVjaGV0

LCBGLiBYLjwvYXV0aG9yPjxhdXRob3I+VmlsbGUsIFkuPC9hdXRob3I+PGF1dGhvcj5Db2hlbiwg

SC48L2F1dGhvcj48YXV0aG9yPkNvc3RhLCBKLiBNLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPlNlcnZpY2UgZGUgR3luZWNvbG9naWUtT2JzdGV0cmlxdWUg

ZXQgTWVkZWNpbmUgZGUgbGEgUmVwcm9kdWN0aW9uLCBIb3BpdGFsIEFudG9pbmUgQmVjbGVyZSwg

VW5pdmVyc2l0ZSBQYXJpcyBTdWQsIENsYW1hcnQsIEZyYW5jZS4mI3hEO0xhYm9yYXRvaXJlIGRl

IEJpb2xvZ2llIE1lZGljYWxlLCBQYXJpcywgRnJhbmNlLiYjeEQ7U2VydmljZSBkZSBHeW5lY29s

b2dpZS1PYnN0ZXRyaXF1ZSwgSG9waXRhbCBOZWNrZXItRW5mYW50cyBNYWxhZGVzLCBQYXJpcywg

RnJhbmNlLiYjeEQ7RGVwYXJ0ZW1lbnQgTWVyZS1FbmZhbnQsIEluc3RpdHV0IE1vbnRzb3VyaXMs

IFBhcmlzLCBGcmFuY2UuJiN4RDtEZXBhcnRlbWVudCBkZSBCaW9sb2dpZSBTcGVjaWFsaXNlZSBl

dCBkZSBHZW5ldGlxdWUsIExhYm9yYXRvaXJlIENFUkJBLCBTYWludC1PdWVuIGwmYXBvcztBdW1v

bmUsIEZyYW5jZS4gRWxlY3Ryb25pYyBhZGRyZXNzOiBqbWNvc3RhQGxhYi1jZXJiYS5jb20uPC9h

dXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RGlhZ25vc3RpYyBhY2N1cmFjeSBvZiBmZXRhbCBy

aGVzdXMgRCBnZW5vdHlwaW5nIHVzaW5nIGNlbGwtZnJlZSBmZXRhbCBETkEgZHVyaW5nIHRoZSBm

aXJzdCB0cmltZXN0ZXIgb2YgcHJlZ25hbmN5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFtIEog

T2JzdGV0IEd5bmVjb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5BbSBKIE9ic3RldCBHeW5lY29sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn

ZXM+NjA2IGUxLTYwNiBlNTwvcGFnZXM+PHZvbHVtZT4yMTU8L3ZvbHVtZT48bnVtYmVyPjU8L251

bWJlcj48ZWRpdGlvbj4yMDE2LzEwLzMwPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVs

dDwva2V5d29yZD48a2V5d29yZD5CbG9vZCBHcm91cCBJbmNvbXBhdGliaWxpdHkvIGRpYWdub3Np

cy9kcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RE5BLyBibG9vZDwva2V5d29yZD48a2V5

d29yZD5FeG9uczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+RmV0

dXMvIG1ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+R2Vub3R5cGluZyBUZWNobmlxdWVzPC9r

ZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdv

cmQ+PGtleXdvcmQ+UHJlZ25hbmN5IFRyaW1lc3RlciwgRmlyc3Q8L2tleXdvcmQ+PGtleXdvcmQ+

UmVhbC1UaW1lIFBvbHltZXJhc2UgQ2hhaW4gUmVhY3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+UmV0

cm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdyb3VwIFN5

c3RlbS8gZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+UmhvKEQpIEltbXVuZSBHbG9idWxpbi90

aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+U2Vuc2l0aXZpdHkgYW5kIFNwZWNpZmlj

aXR5PC9rZXl3b3JkPjxrZXl3b3JkPlJIRCBnZW5vdHlwaW5nPC9rZXl3b3JkPjxrZXl3b3JkPmNl

bGwtZnJlZSBmZXRhbCBETkE8L2tleXdvcmQ+PGtleXdvcmQ+bWF0ZXJuYWwgc2VydW08L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk5v

djwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjEwOTctNjg2OCAoRWxlY3Ryb25pYykm

I3hEOzAwMDItOTM3OCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjczOTMyNzE8L2Fj

Y2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vYWMuZWxzLWNkbi5j

b20vUzAwMDI5Mzc4MTYzMDM5OTQvMS1zMi4wLVMwMDAyOTM3ODE2MzAzOTk0LW1haW4ucGRmP190

aWQ9ZGY1YmI0YjUtN2RiYS00NmY0LWI1OTEtYmY1ZWQ3MmEwOTJjJmFtcDthY2RuYXQ9MTUzMzEw

Njk3NF81ODU0MzhjZTZjYmYwOWEyODA1N2NhYzg3YTkxOGQzZjwvdXJsPjwvcmVsYXRlZC11cmxz

PjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9qLmFqb2cuMjAxNi4wNi4w

NTQ8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxN

PC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNv

cmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 11416 serum samples from RhD-negative pregnant women were collected during the first trimester of pregnancy. Cell-free fetal DNA was extracted from maternal blood of both non-immunised and immunised women at 10-14 weeks of gestation. RHD sequence was determined by quantitative PCR, with amplification of exon 10. Results were compared with RhD phenotype data obtained by cord blood sampling of neonates. analysisCost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis ADDIN EN.CITE <EndNote><Cite><Author>Neovius</Author><Year>2016</Year><RecNum>16</RecNum><IDText>26663771</IDText><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533101424">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Neovius, M.</author><author>Tiblad, E.</author><author>Westgren, M.</author><author>Kublickas, M.</author><author>Neovius, K.</author><author>Wikman, A.</author></authors></contributors><auth-address>Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.Obstetrics & Gynaecology Unit, CLINTEC, Karolinska Institutet, Stockholm, Sweden.Aux Analysis AB, Stockholm, Sweden.Department of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden.</auth-address><titles><title>Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis</title><secondary-title>BJOG</secondary-title></titles><periodical><full-title>BJOG</full-title></periodical><pages>1337-46</pages><volume>123</volume><number>8</number><edition>2015/12/15</edition><keywords><keyword>Cost-effectiveness</keyword><keyword>Rhesus D immunisation</keyword><keyword>fetal screening</keyword></keywords><dates><year>2016</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>1471-0528 (Electronic)1470-0328 (Linking)</isbn><accession-num>26663771</accession-num><urls><related-urls><url> (Sweden) cohort study to estimate the cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal versus no routine antenatal anti-D prophylaxis (RAADP) or versus non-targeted RAADP. Intervention subjects in the underlying cohort study were RhD-negative pregnant women receiving first trimester fetal RHD screening followed by targeted anti-D in 2010–2011 (n = 6723). Historical comparators were RhD-negative women who delivered in 2008–2009 when standard care did not include RAADP (n = 7099). accuracySensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the NetherlandsPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5kZSBIYWFzPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjk8L1JlY051bT48SURUZXh0PjI3ODIxNzAxPC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTM8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj45PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA4MzEiPjk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPmRlIEhhYXMs

IE0uPC9hdXRob3I+PGF1dGhvcj5UaHVyaWssIEYuIEYuPC9hdXRob3I+PGF1dGhvcj52YW4gZGVy

IFBsb2VnLCBDLiBQLjwvYXV0aG9yPjxhdXRob3I+VmVsZGh1aXNlbiwgQi48L2F1dGhvcj48YXV0

aG9yPkhpcnNjaGJlcmcsIEguPC9hdXRob3I+PGF1dGhvcj5Tb3Vzc2FuLCBBLiBBLjwvYXV0aG9y

PjxhdXRob3I+V29vcnRtZWlqZXIsIEguPC9hdXRob3I+PGF1dGhvcj5BYmJpbmssIEYuPC9hdXRo

b3I+PGF1dGhvcj5QYWdlLUNocmlzdGlhZW5zLCBHLiBDLjwvYXV0aG9yPjxhdXRob3I+U2NoZWZm

ZXIsIFAuIEcuPC9hdXRob3I+PGF1dGhvcj5FbGxlbiB2YW4gZGVyIFNjaG9vdCwgQy48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIEV4

cGVyaW1lbnRhbCBJbW11bm9oZW1hdG9sb2d5LCBTYW5xdWluIFJlc2VhcmNoLCBBbXN0ZXJkYW0g

YW5kIExhbmRzdGVpbmVyIExhYm9yYXRvcnksIEFjYWRlbWljIE1lZGljYWwgQ2VudGVyLCBVbml2

ZXJzaXR5IG9mIEFtc3RlcmRhbSwgQW1zdGVyZGFtLCBOZXRoZXJsYW5kcy4mI3hEO0NlbnRlciBm

b3IgQ2xpbmljYWwgVHJhbnNmdXNpb24gUmVzZWFyY2gsIFNhbnF1aW4gUmVzZWFyY2ggYW5kIERl

cGFydG1lbnQgb2YgSW1tdW5vaGVtYXRvbG9neSBhbmQgQmxvb2QgVHJhbnNmdXNpb24sIExlaWRl

biBVbml2ZXJzaXR5IE1lZGljYWwgQ2VudGVyLCBMZWlkZW4uJiN4RDtEZXBhcnRtZW50IG9mIElt

bXVub2hlbWF0b2xvZ3kgRGlhZ25vc3RpYyBTZXJ2aWNlcywgU2FucXVpbiBSZXNlYXJjaCwgQW1z

dGVyZGFtLCBOZXRoZXJsYW5kcy4mI3hEO1VuaXZlcnNpdHkgTWVkaWNhbCBDZW50ZXIgVXRyZWNo

dCwgRGl2aXNpb24gV29tYW4gYW5kIEJhYnksIERlcGFydG1lbnQgb2YgT2JzdGV0cmljcywgVXRy

ZWNodCwgTmV0aGVybGFuZHMuJiN4RDtOZXRoZXJsYW5kcyBPcmdhbml6YXRpb24gZm9yIEFwcGxp

ZWQgU2NpZW50aWZpYyBSZXNlYXJjaCwgRGVwYXJ0bWVudCBvZiBDaGlsZCBIZWFsdGgsIExlaWRl

biwgTmV0aGVybGFuZHMuJiN4RDtOYXRpb25hbCBJbnN0aXR1dGUgZm9yIFB1YmxpYyBIZWFsdGgg

YW5kIHRoZSBFbnZpcm9ubWVudCwgU2VydmljZSBmb3IgdmFjY2luZSBwcm92aXNpb24gYW5kIHBy

ZXZlbnRpb24gcHJvZ3JhbXMsIEJpbHRob3ZlbiwgTmV0aGVybGFuZHMuJiN4RDtOYXRpb25hbCBJ

bnN0aXR1dGUgZm9yIFB1YmxpYyBIZWFsdGggYW5kIHRoZSBFbnZpcm9ubWVudCwgQ2VudGVyIGZv

ciBwb3B1bGF0aW9uIHNjcmVlbmluZywgQmlsdGhvdmVuLCBOZXRoZXJsYW5kcy48L2F1dGgtYWRk

cmVzcz48dGl0bGVzPjx0aXRsZT5TZW5zaXRpdml0eSBvZiBmZXRhbCBSSEQgc2NyZWVuaW5nIGZv

ciBzYWZlIGd1aWRhbmNlIG9mIHRhcmdldGVkIGFudGktRCBpbW11bm9nbG9idWxpbiBwcm9waHls

YXhpczogcHJvc3BlY3RpdmUgY29ob3J0IHN0dWR5IG9mIGEgbmF0aW9ud2lkZSBwcm9ncmFtbWUg

aW4gdGhlIE5ldGhlcmxhbmRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkJNSjwvc2Vjb25kYXJ5

LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkJNSjwvZnVsbC10aXRsZT48

L3BlcmlvZGljYWw+PHBhZ2VzPmk1Nzg5PC9wYWdlcz48dm9sdW1lPjM1NTwvdm9sdW1lPjxlZGl0

aW9uPjIwMTYvMTEvMDk8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkROQS9pc29sYXRpb24g

JmFtcDsgcHVyaWZpY2F0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5

d29yZD5GZXRhbCBCbG9vZC9jaGVtaXN0cnk8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3

b3JkPjxrZXl3b3JkPk5ldGhlcmxhbmRzPC9rZXl3b3JkPjxrZXl3b3JkPlByZWRpY3RpdmUgVmFs

dWUgb2YgVGVzdHM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3Jk

PlByZWduYW5jeSBDb21wbGljYXRpb25zLCBIZW1hdG9sb2dpYy9ibG9vZDwva2V5d29yZD48a2V5

d29yZD5QcmVuYXRhbCBEaWFnbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1

ZGllczwva2V5d29yZD48a2V5d29yZD5SZWFsLVRpbWUgUG9seW1lcmFzZSBDaGFpbiBSZWFjdGlv

bjwva2V5d29yZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGRpYWdub3Npcy9nZW5ldGlj

cy90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdyb3VwIFN5c3RlbS8gZ2Vu

ZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+UmhvKEQpIEltbXVuZSBHbG9idWxpbi9hZG1pbmlzdHJh

dGlvbiAmYW1wOyBkb3NhZ2UvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+U2Vuc2l0aXZpdHkg

YW5kIFNwZWNpZmljaXR5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTY8L3ll

YXI+PHB1Yi1kYXRlcz48ZGF0ZT5Ob3YgNzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjE3NTYtMTgzMyAoRWxlY3Ryb25pYykmI3hEOzA5NTktODEzOCAoTGlua2luZyk8L2lzYm4+PGFj

Y2Vzc2lvbi1udW0+Mjc4MjE3MDE8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48

dXJsPmh0dHBzOi8vd3d3LmJtai5jb20vY29udGVudC9ibWovMzU1L2Jtai5pNTc4OS5mdWxsLnBk

ZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM1MDk4NTQ5IHd3dy5pY21q

ZS5vcmcvY29pX2Rpc2Nsb3N1cmUucGRmIGFuZCBkZWNsYXJlOiBubyBzdXBwb3J0IGZyb20gYW55

IG9yZ2FuaXNhdGlvbiBmb3IgdGhlIHN1Ym1pdHRlZCB3b3JrOyBubyBmaW5hbmNpYWwgcmVsYXRp

b25zaGlwcyB3aXRoIGFueSBvcmdhbmlzYXRpb25zIHRoYXQgbWlnaHQgaGF2ZSBhbiBpbnRlcmVz

dCBpbiB0aGUgc3VibWl0dGVkIHdvcmsgaW4gdGhlIHByZXZpb3VzIHRocmVlIHllYXJzOyBubyBv

dGhlciByZWxhdGlvbnNoaXBzIG9yIGFjdGl2aXRpZXMgdGhhdCBjb3VsZCBhcHBlYXIgdG8gaGF2

ZSBpbmZsdWVuY2VkIHRoZSBzdWJtaXR0ZWQgd29yay48L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjEwLjExMzYvYm1qLmk1Nzg5PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5n

dWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5kZSBIYWFzPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjk8L1JlY051bT48SURUZXh0PjI3ODIxNzAxPC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTM8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj45PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA4MzEiPjk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPmRlIEhhYXMs

IE0uPC9hdXRob3I+PGF1dGhvcj5UaHVyaWssIEYuIEYuPC9hdXRob3I+PGF1dGhvcj52YW4gZGVy

IFBsb2VnLCBDLiBQLjwvYXV0aG9yPjxhdXRob3I+VmVsZGh1aXNlbiwgQi48L2F1dGhvcj48YXV0

aG9yPkhpcnNjaGJlcmcsIEguPC9hdXRob3I+PGF1dGhvcj5Tb3Vzc2FuLCBBLiBBLjwvYXV0aG9y

PjxhdXRob3I+V29vcnRtZWlqZXIsIEguPC9hdXRob3I+PGF1dGhvcj5BYmJpbmssIEYuPC9hdXRo

b3I+PGF1dGhvcj5QYWdlLUNocmlzdGlhZW5zLCBHLiBDLjwvYXV0aG9yPjxhdXRob3I+U2NoZWZm

ZXIsIFAuIEcuPC9hdXRob3I+PGF1dGhvcj5FbGxlbiB2YW4gZGVyIFNjaG9vdCwgQy48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIEV4

cGVyaW1lbnRhbCBJbW11bm9oZW1hdG9sb2d5LCBTYW5xdWluIFJlc2VhcmNoLCBBbXN0ZXJkYW0g

YW5kIExhbmRzdGVpbmVyIExhYm9yYXRvcnksIEFjYWRlbWljIE1lZGljYWwgQ2VudGVyLCBVbml2

ZXJzaXR5IG9mIEFtc3RlcmRhbSwgQW1zdGVyZGFtLCBOZXRoZXJsYW5kcy4mI3hEO0NlbnRlciBm

b3IgQ2xpbmljYWwgVHJhbnNmdXNpb24gUmVzZWFyY2gsIFNhbnF1aW4gUmVzZWFyY2ggYW5kIERl

cGFydG1lbnQgb2YgSW1tdW5vaGVtYXRvbG9neSBhbmQgQmxvb2QgVHJhbnNmdXNpb24sIExlaWRl

biBVbml2ZXJzaXR5IE1lZGljYWwgQ2VudGVyLCBMZWlkZW4uJiN4RDtEZXBhcnRtZW50IG9mIElt

bXVub2hlbWF0b2xvZ3kgRGlhZ25vc3RpYyBTZXJ2aWNlcywgU2FucXVpbiBSZXNlYXJjaCwgQW1z

dGVyZGFtLCBOZXRoZXJsYW5kcy4mI3hEO1VuaXZlcnNpdHkgTWVkaWNhbCBDZW50ZXIgVXRyZWNo

dCwgRGl2aXNpb24gV29tYW4gYW5kIEJhYnksIERlcGFydG1lbnQgb2YgT2JzdGV0cmljcywgVXRy

ZWNodCwgTmV0aGVybGFuZHMuJiN4RDtOZXRoZXJsYW5kcyBPcmdhbml6YXRpb24gZm9yIEFwcGxp

ZWQgU2NpZW50aWZpYyBSZXNlYXJjaCwgRGVwYXJ0bWVudCBvZiBDaGlsZCBIZWFsdGgsIExlaWRl

biwgTmV0aGVybGFuZHMuJiN4RDtOYXRpb25hbCBJbnN0aXR1dGUgZm9yIFB1YmxpYyBIZWFsdGgg

YW5kIHRoZSBFbnZpcm9ubWVudCwgU2VydmljZSBmb3IgdmFjY2luZSBwcm92aXNpb24gYW5kIHBy

ZXZlbnRpb24gcHJvZ3JhbXMsIEJpbHRob3ZlbiwgTmV0aGVybGFuZHMuJiN4RDtOYXRpb25hbCBJ

bnN0aXR1dGUgZm9yIFB1YmxpYyBIZWFsdGggYW5kIHRoZSBFbnZpcm9ubWVudCwgQ2VudGVyIGZv

ciBwb3B1bGF0aW9uIHNjcmVlbmluZywgQmlsdGhvdmVuLCBOZXRoZXJsYW5kcy48L2F1dGgtYWRk

cmVzcz48dGl0bGVzPjx0aXRsZT5TZW5zaXRpdml0eSBvZiBmZXRhbCBSSEQgc2NyZWVuaW5nIGZv

ciBzYWZlIGd1aWRhbmNlIG9mIHRhcmdldGVkIGFudGktRCBpbW11bm9nbG9idWxpbiBwcm9waHls

YXhpczogcHJvc3BlY3RpdmUgY29ob3J0IHN0dWR5IG9mIGEgbmF0aW9ud2lkZSBwcm9ncmFtbWUg

aW4gdGhlIE5ldGhlcmxhbmRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkJNSjwvc2Vjb25kYXJ5

LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkJNSjwvZnVsbC10aXRsZT48

L3BlcmlvZGljYWw+PHBhZ2VzPmk1Nzg5PC9wYWdlcz48dm9sdW1lPjM1NTwvdm9sdW1lPjxlZGl0

aW9uPjIwMTYvMTEvMDk8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkROQS9pc29sYXRpb24g

JmFtcDsgcHVyaWZpY2F0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5

d29yZD5GZXRhbCBCbG9vZC9jaGVtaXN0cnk8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3

b3JkPjxrZXl3b3JkPk5ldGhlcmxhbmRzPC9rZXl3b3JkPjxrZXl3b3JkPlByZWRpY3RpdmUgVmFs

dWUgb2YgVGVzdHM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3Jk

PlByZWduYW5jeSBDb21wbGljYXRpb25zLCBIZW1hdG9sb2dpYy9ibG9vZDwva2V5d29yZD48a2V5

d29yZD5QcmVuYXRhbCBEaWFnbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1

ZGllczwva2V5d29yZD48a2V5d29yZD5SZWFsLVRpbWUgUG9seW1lcmFzZSBDaGFpbiBSZWFjdGlv

bjwva2V5d29yZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGRpYWdub3Npcy9nZW5ldGlj

cy90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdyb3VwIFN5c3RlbS8gZ2Vu

ZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+UmhvKEQpIEltbXVuZSBHbG9idWxpbi9hZG1pbmlzdHJh

dGlvbiAmYW1wOyBkb3NhZ2UvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+U2Vuc2l0aXZpdHkg

YW5kIFNwZWNpZmljaXR5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTY8L3ll

YXI+PHB1Yi1kYXRlcz48ZGF0ZT5Ob3YgNzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjE3NTYtMTgzMyAoRWxlY3Ryb25pYykmI3hEOzA5NTktODEzOCAoTGlua2luZyk8L2lzYm4+PGFj

Y2Vzc2lvbi1udW0+Mjc4MjE3MDE8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48

dXJsPmh0dHBzOi8vd3d3LmJtai5jb20vY29udGVudC9ibWovMzU1L2Jtai5pNTc4OS5mdWxsLnBk

ZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM1MDk4NTQ5IHd3dy5pY21q

ZS5vcmcvY29pX2Rpc2Nsb3N1cmUucGRmIGFuZCBkZWNsYXJlOiBubyBzdXBwb3J0IGZyb20gYW55

IG9yZ2FuaXNhdGlvbiBmb3IgdGhlIHN1Ym1pdHRlZCB3b3JrOyBubyBmaW5hbmNpYWwgcmVsYXRp

b25zaGlwcyB3aXRoIGFueSBvcmdhbmlzYXRpb25zIHRoYXQgbWlnaHQgaGF2ZSBhbiBpbnRlcmVz

dCBpbiB0aGUgc3VibWl0dGVkIHdvcmsgaW4gdGhlIHByZXZpb3VzIHRocmVlIHllYXJzOyBubyBv

dGhlciByZWxhdGlvbnNoaXBzIG9yIGFjdGl2aXRpZXMgdGhhdCBjb3VsZCBhcHBlYXIgdG8gaGF2

ZSBpbmZsdWVuY2VkIHRoZSBzdWJtaXR0ZWQgd29yay48L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjEwLjExMzYvYm1qLmk1Nzg5PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5n

dWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA 13Fetal RHD testing was performed with a duplex real time quantitative PCR, with cell-free fetal DNA isolated from maternal plasma and compared to serological cord blood typing. A fetal RHD test result and serological cord blood result were available for 25,789 pregnancies. Sensitivity and specificity for detection of fetal RHD was 99.94% and 97.74%, respectively. Nine false negative results for fetal RHD testing were registered, 2 of which were due to technical failures. False positive fetal RHD testing results were registered for 225 samples. Weak RhD expression was shown in 22 of these cases, justifying anti-D immunoglobulin use. The negative and positive predictive values were 99.91% and 98.60%, respectively. More than 98% of the women participated in the screening programme. analysisCosts and benefits of non-invasive fetal RhD determinationPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UZWl0ZWxiYXVtPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh

cj48UmVjTnVtPjE3PC9SZWNOdW0+PElEVGV4dD4yNTM4MDAyNDwvSURUZXh0PjxEaXNwbGF5VGV4

dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjE0PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MTc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJycHYyMGFkYWU5dHNkNmVhczBkcDkwc3d4ZHR2MGEyOXMyMHMiIHRpbWVzdGFtcD0i

MTUzMzEwMTQyNCI+MTc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlRl

aXRlbGJhdW0sIEwuPC9hdXRob3I+PGF1dGhvcj5NZXRjYWxmZSwgQS48L2F1dGhvcj48YXV0aG9y

PkNsYXJrZSwgRy48L2F1dGhvcj48YXV0aG9yPlBhcmJvb3NpbmdoLCBKLiBTLjwvYXV0aG9yPjxh

dXRob3I+V2lsc29uLCBSLiBELjwvYXV0aG9yPjxhdXRob3I+Sm9obnNvbiwgSi4gTS48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE9i

c3RldHJpY3MgYW5kIEd5bmVjb2xvZ3ksIFVuaXZlcnNpdHkgb2YgQ2FsZ2FyeSwgQ2FsZ2FyeSwg

QWxiZXJ0YSwgQ2FuYWRhLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNvc3RzIGFuZCBi

ZW5lZml0cyBvZiBub24taW52YXNpdmUgZmV0YWwgUmhEIGRldGVybWluYXRpb248L3RpdGxlPjxz

ZWNvbmRhcnktdGl0bGU+VWx0cmFzb3VuZCBPYnN0ZXQgR3luZWNvbDwvc2Vjb25kYXJ5LXRpdGxl

PjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPlVsdHJhc291bmQgT2JzdGV0IEd5bmVj

b2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz44NC04PC9wYWdlcz48dm9sdW1lPjQ1

PC92b2x1bWU+PG51bWJlcj4xPC9udW1iZXI+PGVkaXRpb24+MjAxNC8xMS8wODwvZWRpdGlvbj48

a2V5d29yZHM+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2FuYWRhPC9rZXl3b3Jk

PjxrZXl3b3JkPkNlbGwtRnJlZSBTeXN0ZW08L2tleXdvcmQ+PGtleXdvcmQ+Q29zdC1CZW5lZml0

IEFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkROQS8gYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+

RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmZhbnQs

IE5ld2Jvcm48L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlBy

ZWduYW5jeSBDb21wbGljYXRpb25zLCBIZW1hdG9sb2dpYy9lY29ub21pY3MvIHByZXZlbnRpb24g

JmFtcDsgY29udHJvbDwva2V5d29yZD48a2V5d29yZD5Qcm9ncmFtIEV2YWx1YXRpb248L2tleXdv

cmQ+PGtleXdvcmQ+UmggSXNvaW1tdW5pemF0aW9uL2Vjb25vbWljcy8gcHJldmVudGlvbiAmYW1w

OyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdyb3VwIFN5c3RlbTwva2V5

d29yZD48a2V5d29yZD5SaG8oRCkgSW1tdW5lIEdsb2J1bGluL2Vjb25vbWljcy8gdGhlcmFwZXV0

aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPmFudGVuYXRhbCBhbnRpLVJoRCBwcm9waHlsYXhpczwv

a2V5d29yZD48a2V5d29yZD5jZWxsLWZyZWUgZmV0YWwgRE5BPC9rZXl3b3JkPjxrZXl3b3JkPmNv

c3Q8L2tleXdvcmQ+PGtleXdvcmQ+ZmV0YWwgUmhEIGRldGVybWluYXRpb248L2tleXdvcmQ+PGtl

eXdvcmQ+bm9uLWludmFzaXZlIHByZW5hdGFsIHRlc3Rpbmc8L2tleXdvcmQ+PC9rZXl3b3Jkcz48

ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1k

YXRlcz48L2RhdGVzPjxpc2JuPjE0NjktMDcwNSAoRWxlY3Ryb25pYykmI3hEOzA5NjAtNzY5MiAo

TGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjUzODAwMjQ8L2FjY2Vzc2lvbi1udW0+PHVy

bHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vb2JneW4ub25saW5lbGlicmFyeS53aWxleS5j

b20vZG9pL3BkZi8xMC4xMDAyL3VvZy4xNDcyMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48

ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAwMi91b2cuMTQ3MjM8L2VsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2Ut

cHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90

ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UZWl0ZWxiYXVtPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh

cj48UmVjTnVtPjE3PC9SZWNOdW0+PElEVGV4dD4yNTM4MDAyNDwvSURUZXh0PjxEaXNwbGF5VGV4

dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjE0PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MTc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJycHYyMGFkYWU5dHNkNmVhczBkcDkwc3d4ZHR2MGEyOXMyMHMiIHRpbWVzdGFtcD0i

MTUzMzEwMTQyNCI+MTc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlRl

aXRlbGJhdW0sIEwuPC9hdXRob3I+PGF1dGhvcj5NZXRjYWxmZSwgQS48L2F1dGhvcj48YXV0aG9y

PkNsYXJrZSwgRy48L2F1dGhvcj48YXV0aG9yPlBhcmJvb3NpbmdoLCBKLiBTLjwvYXV0aG9yPjxh

dXRob3I+V2lsc29uLCBSLiBELjwvYXV0aG9yPjxhdXRob3I+Sm9obnNvbiwgSi4gTS48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE9i

c3RldHJpY3MgYW5kIEd5bmVjb2xvZ3ksIFVuaXZlcnNpdHkgb2YgQ2FsZ2FyeSwgQ2FsZ2FyeSwg

QWxiZXJ0YSwgQ2FuYWRhLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNvc3RzIGFuZCBi

ZW5lZml0cyBvZiBub24taW52YXNpdmUgZmV0YWwgUmhEIGRldGVybWluYXRpb248L3RpdGxlPjxz

ZWNvbmRhcnktdGl0bGU+VWx0cmFzb3VuZCBPYnN0ZXQgR3luZWNvbDwvc2Vjb25kYXJ5LXRpdGxl

PjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPlVsdHJhc291bmQgT2JzdGV0IEd5bmVj

b2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz44NC04PC9wYWdlcz48dm9sdW1lPjQ1

PC92b2x1bWU+PG51bWJlcj4xPC9udW1iZXI+PGVkaXRpb24+MjAxNC8xMS8wODwvZWRpdGlvbj48

a2V5d29yZHM+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2FuYWRhPC9rZXl3b3Jk

PjxrZXl3b3JkPkNlbGwtRnJlZSBTeXN0ZW08L2tleXdvcmQ+PGtleXdvcmQ+Q29zdC1CZW5lZml0

IEFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkROQS8gYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+

RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmZhbnQs

IE5ld2Jvcm48L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlBy

ZWduYW5jeSBDb21wbGljYXRpb25zLCBIZW1hdG9sb2dpYy9lY29ub21pY3MvIHByZXZlbnRpb24g

JmFtcDsgY29udHJvbDwva2V5d29yZD48a2V5d29yZD5Qcm9ncmFtIEV2YWx1YXRpb248L2tleXdv

cmQ+PGtleXdvcmQ+UmggSXNvaW1tdW5pemF0aW9uL2Vjb25vbWljcy8gcHJldmVudGlvbiAmYW1w

OyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdyb3VwIFN5c3RlbTwva2V5

d29yZD48a2V5d29yZD5SaG8oRCkgSW1tdW5lIEdsb2J1bGluL2Vjb25vbWljcy8gdGhlcmFwZXV0

aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPmFudGVuYXRhbCBhbnRpLVJoRCBwcm9waHlsYXhpczwv

a2V5d29yZD48a2V5d29yZD5jZWxsLWZyZWUgZmV0YWwgRE5BPC9rZXl3b3JkPjxrZXl3b3JkPmNv

c3Q8L2tleXdvcmQ+PGtleXdvcmQ+ZmV0YWwgUmhEIGRldGVybWluYXRpb248L2tleXdvcmQ+PGtl

eXdvcmQ+bm9uLWludmFzaXZlIHByZW5hdGFsIHRlc3Rpbmc8L2tleXdvcmQ+PC9rZXl3b3Jkcz48

ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1k

YXRlcz48L2RhdGVzPjxpc2JuPjE0NjktMDcwNSAoRWxlY3Ryb25pYykmI3hEOzA5NjAtNzY5MiAo

TGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjUzODAwMjQ8L2FjY2Vzc2lvbi1udW0+PHVy

bHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vb2JneW4ub25saW5lbGlicmFyeS53aWxleS5j

b20vZG9pL3BkZi8xMC4xMDAyL3VvZy4xNDcyMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48

ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAwMi91b2cuMTQ3MjM8L2VsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2Ut

cHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90

ZT5=

ADDIN EN.CITE.DATA 14A decision analysis based on a theoretical population representing the total number of pregnancies in Alberta over a 1-year period (n=69 286). A decision tree was created that outlined targeted prophylaxis for unsensitised RhD-negative pregnant women screened for cffDNA (targeted group) vs routine prophylaxis for all unsensitised RhD-negative pregnant women (routine group). Probabilities at each decision point and costs associated with each resource were calculated from local clinical and administrative data. The estimated cost per pregnancy for the routine group was C$71.43 compared with C$67.20 in the targeted group. Sensitization rates per RhD-negative pregnancy were equal, at 0.0012, for the current and targeted programs. Implementing targeted antenatal anti-RhD prophylaxis would save 4,072 doses (20.1%) of RhIG over a 1-year period in Alberta when compared to the current program. accuracyUse of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHSPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Tb290aGlsbDwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+

PFJlY051bT4yODwvUmVjTnVtPjxJRFRleHQ+MjUxNDIxNzE8L0lEVGV4dD48RGlzcGxheVRleHQ+

PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4xNTwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjI4PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1

MzMxMDYwNDAiPjI4PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Tb290

aGlsbCwgUC4gVy48L2F1dGhvcj48YXV0aG9yPkZpbm5pbmcsIEsuPC9hdXRob3I+PGF1dGhvcj5M

YXRoYW0sIFQuPC9hdXRob3I+PGF1dGhvcj5XcmVmb3JkLUJ1c2gsIFQuPC9hdXRob3I+PGF1dGhv

cj5Gb3JkLCBKLjwvYXV0aG9yPjxhdXRob3I+RGFuaWVscywgRy48L2F1dGhvcj48L2F1dGhvcnM+

PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5GZXRhbCBNZWRpY2luZSBVbml0LCBTdCBNaWNo

YWVscyBIb3NwaXRhbCwgVW5pdmVyc2l0eSBIb3NwaXRhbHMgQnJpc3RvbCBOSFMgRm91bmRhdGlv

biBUcnVzdCwgQnJpc3RvbCwgVUsuJiN4RDtOSFMgQmxvb2QgYW5kIFRyYW5zcGxhbnQsIEludGVy

bmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9yYXRvcnksIEZpbHRvbiwgQnJpc3Rv

bCwgVUsuJiN4RDtIYWVtYXRvbG9neSwgU291dGhtZWFkIEhvc3BpdGFsLCBXZXN0YnVyeS1vbi1U

cnltLCBCcmlzdG9sLCBVSy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Vc2Ugb2YgY2Zm

RE5BIHRvIGF2b2lkIGFkbWluaXN0cmF0aW9uIG9mIGFudGktRCB0byBwcmVnbmFudCB3b21lbiB3

aGVuIHRoZSBmZXR1cyBpcyBSaEQtbmVnYXRpdmU6IGltcGxlbWVudGF0aW9uIGluIHRoZSBOSFM8

L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QkpPRzwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxw

ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkJKT0c8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdl

cz4xNjgyLTY8L3BhZ2VzPjx2b2x1bWU+MTIyPC92b2x1bWU+PG51bWJlcj4xMjwvbnVtYmVyPjxl

ZGl0aW9uPjIwMTQvMDgvMjI8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkbWluaXN0cmF0

aW9uLCBJbnRyYXZlbm91czwva2V5d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29y

ZD5BbmVtaWEsIEhlbW9seXRpYy8gcHJldmVudGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxr

ZXl3b3JkPkNyb3NzLVNlY3Rpb25hbCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwv

a2V5d29yZD48a2V5d29yZD5IZWFsdGggUG9saWN5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwv

a2V5d29yZD48a2V5d29yZD5JbW11bm9sb2dpYyBGYWN0b3JzLyBhZG1pbmlzdHJhdGlvbiAmYW1w

OyBkb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+SXNvYW50aWJvZGllcy8gYWRtaW5pc3RyYXRpb24g

JmFtcDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3JkPlByYWN0aWNlIEd1aWRlbGluZXMgYXMgVG9w

aWM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByb3NwZWN0

aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmggSXNvaW1tdW5pemF0aW9uLyBibG9vZDwv

a2V5d29yZD48a2V5d29yZD5SaC1IciBCbG9vZC1Hcm91cCBTeXN0ZW0vIGdlbmV0aWNzPC9rZXl3

b3JkPjxrZXl3b3JkPlN0YXRlIE1lZGljaW5lPC9rZXl3b3JkPjxrZXl3b3JkPkFudGktRDwva2V5

d29yZD48a2V5d29yZD5SaGQ8L2tleXdvcmQ+PGtleXdvcmQ+Y2ZmRE5BPC9rZXl3b3JkPjxrZXl3

b3JkPm5vbi1pbnZhc2l2ZSBwcmVuYXRhbCB0ZXN0aW5nPC9rZXl3b3JkPjxrZXl3b3JkPnJoZXN1

cyBkaXNlYXNlPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1

Yi1kYXRlcz48ZGF0ZT5Ob3Y8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDcxLTA1

MjggKEVsZWN0cm9uaWMpJiN4RDsxNDcwLTAzMjggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjI1MTQyMTcxPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL29iZ3luLm9ubGluZWxpYnJhcnkud2lsZXkuY29tL2RvaS9wZGYvMTAuMTExMS8xNDcxLTA1

MjguMTMwNTU8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjEwLjExMTEvMTQ3MS0wNTI4LjEzMDU1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5n

dWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Tb290aGlsbDwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+

PFJlY051bT4yODwvUmVjTnVtPjxJRFRleHQ+MjUxNDIxNzE8L0lEVGV4dD48RGlzcGxheVRleHQ+

PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4xNTwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjI4PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1

MzMxMDYwNDAiPjI4PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Tb290

aGlsbCwgUC4gVy48L2F1dGhvcj48YXV0aG9yPkZpbm5pbmcsIEsuPC9hdXRob3I+PGF1dGhvcj5M

YXRoYW0sIFQuPC9hdXRob3I+PGF1dGhvcj5XcmVmb3JkLUJ1c2gsIFQuPC9hdXRob3I+PGF1dGhv

cj5Gb3JkLCBKLjwvYXV0aG9yPjxhdXRob3I+RGFuaWVscywgRy48L2F1dGhvcj48L2F1dGhvcnM+

PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5GZXRhbCBNZWRpY2luZSBVbml0LCBTdCBNaWNo

YWVscyBIb3NwaXRhbCwgVW5pdmVyc2l0eSBIb3NwaXRhbHMgQnJpc3RvbCBOSFMgRm91bmRhdGlv

biBUcnVzdCwgQnJpc3RvbCwgVUsuJiN4RDtOSFMgQmxvb2QgYW5kIFRyYW5zcGxhbnQsIEludGVy

bmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9yYXRvcnksIEZpbHRvbiwgQnJpc3Rv

bCwgVUsuJiN4RDtIYWVtYXRvbG9neSwgU291dGhtZWFkIEhvc3BpdGFsLCBXZXN0YnVyeS1vbi1U

cnltLCBCcmlzdG9sLCBVSy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Vc2Ugb2YgY2Zm

RE5BIHRvIGF2b2lkIGFkbWluaXN0cmF0aW9uIG9mIGFudGktRCB0byBwcmVnbmFudCB3b21lbiB3

aGVuIHRoZSBmZXR1cyBpcyBSaEQtbmVnYXRpdmU6IGltcGxlbWVudGF0aW9uIGluIHRoZSBOSFM8

L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QkpPRzwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxw

ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkJKT0c8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdl

cz4xNjgyLTY8L3BhZ2VzPjx2b2x1bWU+MTIyPC92b2x1bWU+PG51bWJlcj4xMjwvbnVtYmVyPjxl

ZGl0aW9uPjIwMTQvMDgvMjI8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkbWluaXN0cmF0

aW9uLCBJbnRyYXZlbm91czwva2V5d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29y

ZD5BbmVtaWEsIEhlbW9seXRpYy8gcHJldmVudGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxr

ZXl3b3JkPkNyb3NzLVNlY3Rpb25hbCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwv

a2V5d29yZD48a2V5d29yZD5IZWFsdGggUG9saWN5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwv

a2V5d29yZD48a2V5d29yZD5JbW11bm9sb2dpYyBGYWN0b3JzLyBhZG1pbmlzdHJhdGlvbiAmYW1w

OyBkb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+SXNvYW50aWJvZGllcy8gYWRtaW5pc3RyYXRpb24g

JmFtcDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3JkPlByYWN0aWNlIEd1aWRlbGluZXMgYXMgVG9w

aWM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByb3NwZWN0

aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmggSXNvaW1tdW5pemF0aW9uLyBibG9vZDwv

a2V5d29yZD48a2V5d29yZD5SaC1IciBCbG9vZC1Hcm91cCBTeXN0ZW0vIGdlbmV0aWNzPC9rZXl3

b3JkPjxrZXl3b3JkPlN0YXRlIE1lZGljaW5lPC9rZXl3b3JkPjxrZXl3b3JkPkFudGktRDwva2V5

d29yZD48a2V5d29yZD5SaGQ8L2tleXdvcmQ+PGtleXdvcmQ+Y2ZmRE5BPC9rZXl3b3JkPjxrZXl3

b3JkPm5vbi1pbnZhc2l2ZSBwcmVuYXRhbCB0ZXN0aW5nPC9rZXl3b3JkPjxrZXl3b3JkPnJoZXN1

cyBkaXNlYXNlPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1

Yi1kYXRlcz48ZGF0ZT5Ob3Y8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDcxLTA1

MjggKEVsZWN0cm9uaWMpJiN4RDsxNDcwLTAzMjggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjI1MTQyMTcxPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL29iZ3luLm9ubGluZWxpYnJhcnkud2lsZXkuY29tL2RvaS9wZGYvMTAuMTExMS8xNDcxLTA1

MjguMTMwNTU8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjEwLjExMTEvMTQ3MS0wNTI4LjEzMDU1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5n

dWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE.DATA 15cffDNA testing was offered to all RhD-negative women at about 16 weeks’ gestation in 3 maternity centres (total number not stated). Uptake of testing increased over the time of the pilot study. 529 samples were received; 3 were unsuitable. The results were reported as RhD-positive (n = 278), RhD-negative (n = 185) or inconclusive, treat as positive (n = 63). Cord blood results were available in 502 (95%) and the only incorrect result was one case of a false positive (cffDNA reported as positive, cord blood negative – and so given anti-D unnecessarily). Audit showed that women who declined this service were correctly managed and that anti-D was not given when the fetus was predicted to be RhD-negative. The total use of anti-D doses fell by about 29% which equated to about 35% of RhD-negative women not receiving anti-D in their pregnancy unnecessarily.* Categorise study design, for example meta-analysis, randomised trials, non-randomised trial or observational study, study of diagnostic accuracy, etc. **Provide high level information including population numbers and whether patients are being recruited or in post-recruitment, including providing the trial registration number to allow for tracking purposes.*** If the publication is a follow-up to an initial publication, please advise.Identify yet to be published research that may have results available in the near future that could be relevant in the consideration of your application by MSAC (limiting these to the English language only). Please do not attach full text articles, this is just intended to be a summary.-Type of study design*Title of research (including any trial identifier if relevant)Short description of research (max 50 words)**Website link to research (if available)Date***1.NilNil NilNilNil* Categorise study design, for example meta-analysis, randomised trials, non-randomised trial or observational study, study of diagnostic accuracy, etc. **Provide high level information including population numbers and whether patients are being recruited or in post-recruitment.***Date of when results will be made available (to the best of your knowledge).PART 5 – CLINICAL ENDORSEMENT AND CONSUMER INFORMATIONList all appropriate professional bodies / organisations representing the group(s) of health professionals who provide the service (please attach a statement of clinical relevance from each group nominated):Royal College of Pathologists of Australasia (RCPA)List any professional bodies / organisations that may be impacted by this medical service (i.e. those who provide the comparator service):Australian Red Cross Blood Service Royal Australian and New Zealand College of Obstetricians and GynaecologistsRoyal Australasian College of General PractitionersList the relevant consumer organisations relevant to the proposed medical service (please attach a letter of support for each consumer organisation nominated):Australian Red Cross Blood ServiceList the relevant sponsor(s) and / or manufacturer(s) who produce similar products relevant to the proposed medical service:N/ANominate two experts who could be approached about the proposed medical service and the current clinical management of the service(s):Name of expert 1: REDACTEDTelephone number(s): REDACTEDEmail address: REDACTEDJustification of expertise: REDACTED. Name of expert 2: REDACTEDTelephone number(s): REDACTEDEmail address: REDACTED Justification of expertise: REDACTED.Please note that the Department may also consult with other referrers, proceduralists and disease specialists to obtain their insight.PART 6 – POPULATION (AND PRIOR TESTS), INTERVENTION, COMPARATOR, OUTCOME (PICO)PART 6a – INFORMATION ABOUT THE PROPOSED POPULATIONDefine the medical condition, including providing information on the natural history of the condition and a high-level summary of associated burden of disease in terms of both morbidity and mortality:Although the Rh system comprises 61 antigens, the D antigen is the most immunogenic and important, with routine Rh typing only testing for the presence or absence of the D antigen on red cells. The presence of RhD antigen confers Rh positivity; while people who lack RhD antigen are Rh negative. Approximately one in seven women has a rhesus (Rh) D-negative blood group. RhD negative women carrying an RhD-positive fetus are at risk of becoming sensitised, producing antibodies against the RhD antigen if fetal cells enter the maternal circulation. ADDIN EN.CITE <EndNote><Cite><Author>Lyon</Author><Year>2018</Year><RecNum>49</RecNum><IDText>29726855</IDText><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533107858">49</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lyon, C.</author><author>English, A.</author></authors></contributors><auth-address>University of Colorado Family Medicine Residency Program, Denver, Colorado, USA.</auth-address><titles><title>PURL: A new protocol for RhD-negative pregnant women?</title><secondary-title>J Fam Pract</secondary-title></titles><periodical><full-title>J Fam Pract</full-title></periodical><pages>306;308;319</pages><volume>67</volume><number>5</number><edition>2018/05/05</edition><dates><year>2018</year><pub-dates><date>May</date></pub-dates></dates><isbn>1533-7294 (Electronic)0094-3509 (Linking)</isbn><accession-num>29726855</accession-num><urls><related-urls><url> Although sensitisation can occur at any time during gestation, it usually occurs in the third trimester or during labour. In addition, sensitisation can result from medical interventions (e.g. chorionic villus sampling, amniocentesis or external cephalic version), terminations, late miscarriages, antepartum haemorrhage and abdominal trauma. Sensitisation has no adverse effect on the mother, and usually has no adverse effect on the RhD-positive fetus of the pregnancy during which it occurs. However, future RhD-positive pregnancies in women who have been sensitised to the RhD antigen are at risk of haemolytic disease of the fetus and newborn (HDFN) when the mother mounts an immediate immune response. The mother’s anti-D antibodies respond to the presence of RhD-positive blood in the fetus, cross the placenta and bind to fetal red blood cells, leading to haemolysis. ADDIN EN.CITE <EndNote><Cite><Author>Saramago</Author><Year>2018</Year><RecNum>3</RecNum><IDText>29580376</IDText><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533100529">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Saramago, P.</author><author>Yang, H.</author><author>Llewellyn, A.</author><author>Walker, R.</author><author>Harden, M.</author><author>Palmer, S.</author><author>Griffin, S.</author><author>Simmonds, M.</author></authors></contributors><auth-address>Centre for Health Economics, University of York, York, UK.Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.Centre for Reviews and Dissemination, University of York, York, UK.</auth-address><titles><title>High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation</title><secondary-title>Health Technol Assess</secondary-title></titles><periodical><full-title>Health Technol Assess</full-title></periodical><pages>1-172</pages><volume>22</volume><number>13</number><edition>2018/03/28</edition><dates><year>2018</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>2046-4924 (Electronic)1366-5278 (Linking)</isbn><accession-num>29580376</accession-num><urls></urls><custom2>PMC5890172</custom2><electronic-resource-num>10.3310/hta22130</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>3 If undiagnosed and/or untreated, HDFN carries significant risk of perinatal morbidity, including fetal anaemia and fetal heart failure, fluid retention, and generalised oedema which can be severe (hydrops fetalis), and possibly intrauterine death. In the newborn high levels of bilirubin (caused by the breakdown of red blood cells) can lead to severe neonatal jaundice with an increased risk of permanent brain damage. ADDIN EN.CITE <EndNote><Cite><Author>Gandhi</Author><Year>2016</Year><RecNum>20</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533102635">20</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Gandhi, A.</author></authors></contributors><titles><title>Haemolytic Disease of the Fetus and Newborn</title></titles><volume>2018</volume><number>1st August</number><dates><year>2016</year></dates><publisher>Patient Platform Ltd</publisher><urls><related-urls><url> The risk of HDFN increases with each subsequent pregnancy with a Rh-positive fetus. ADDIN EN.CITE <EndNote><Cite><Author>Gordon</Author><Year>2017</Year><RecNum>15</RecNum><IDText>29096422</IDText><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533101424">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gordon, L. G.</author><author>Hyland, C. A.</author><author>Hyett, J. A.</author><author>O'Brien, H.</author><author>Millard, G.</author><author>Flower, R. L.</author><author>Gardener, G. J.</author></authors></contributors><auth-address>QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Australia.Queensland University of Technology, School of Nursing, Brisbane, Australia.Australian Red Cross Blood Service, Brisbane, Australia.Clinical Professor and Head of High Risk Obstetrics, RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, Australia.Centre for Maternal Fetal Medicine at Mater Mothers' Hospitals, Brisbane, Australia.</auth-address><titles><title>Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis</title><secondary-title>Prenat Diagn</secondary-title></titles><periodical><full-title>Prenat Diagn</full-title></periodical><pages>1245-1253</pages><volume>37</volume><number>12</number><edition>2017/11/03</edition><dates><year>2017</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1097-0223 (Electronic)0197-3851 (Linking)</isbn><accession-num>29096422</accession-num><urls><related-urls><url> current standard of care is the routine administration anti-D immunoglobulin prophylaxis to all RhD negative pregnant women at 28 and 34 weeks’ gestation, and within 72 hours of the delivery of an RhD-positive fetus, or following other obstetric events associated with a risk of fetal-to-maternal haemorrhage. ADDIN EN.CITE <EndNote><Cite><Author>RANZCOG</Author><Year>2015</Year><RecNum>25</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533105490">25</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>RANZCOG</author></authors></contributors><titles><title>Guidelines for the use of Rh(D) Immunoglobulin (Anti-D) in obstetrics in Australia</title></titles><volume>2018</volume><number>1st August</number><dates><year>2015</year></dates><publisher>The Royal Australian and New Zealand College of Obstetricians and Gynaecologists</publisher><urls><related-urls><url> Australian Red Cross Blood Service estimates that approximately 17% of Australian women who become pregnant are RhD-negative and would receive routine anti-D prophylaxis. However, of all RhD-negative pregnant women, approximately 40 per cent will be carrying an RhD-negative fetus and would receive unnecessary anti-D prophylaxis.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaW5uaW5nPC9BdXRob3I+PFllYXI+MjAwODwvWWVhcj48

UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PjE4MzkwNDk2PC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj40PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA2MTciPjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpbm5pbmcs

IEsuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuPC9hdXRob3I+PGF1dGhvcj5TdW1tZXJzLCBK

LjwvYXV0aG9yPjxhdXRob3I+TWFzc2V5LCBFLjwvYXV0aG9yPjxhdXRob3I+UG9vbGUsIEcuPC9h

dXRob3I+PGF1dGhvcj5EYW5pZWxzLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkludGVybmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9y

YXRvcnksIE5IUyBCbG9vZCBhbmQgVHJhbnNwbGFudCwgQnJpc3RvbCBCUzEwIDVORC48L2F1dGgt

YWRkcmVzcz48dGl0bGVzPjx0aXRsZT5FZmZlY3Qgb2YgaGlnaCB0aHJvdWdocHV0IFJIRCB0eXBp

bmcgb2YgZmV0YWwgRE5BIGluIG1hdGVybmFsIHBsYXNtYSBvbiB1c2Ugb2YgYW50aS1SaEQgaW1t

dW5vZ2xvYnVsaW4gaW4gUmhEIG5lZ2F0aXZlIHByZWduYW50IHdvbWVuOiBwcm9zcGVjdGl2ZSBm

ZWFzaWJpbGl0eSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5CTUo8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CTUo8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz44MTYtODwvcGFnZXM+PHZvbHVtZT4zMzY8L3ZvbHVtZT48bnVtYmVy

Pjc2NDg8L251bWJlcj48ZWRpdGlvbj4yMDA4LzA0LzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5

d29yZD5ETkEvIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8

L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIEJsb29kL2No

ZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEaXNlYXNlcy8gZ2VuZXRpY3M8L2tleXdv

cmQ+PGtleXdvcmQ+R2VuZXRpYyBUZWNobmlxdWVzL3N0YW5kYXJkczwva2V5d29yZD48a2V5d29y

ZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29y

ZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29y

ZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk

PlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNlbnNp

dGl2aXR5IGFuZCBTcGVjaWZpY2l0eTwva2V5d29yZD48a2V5d29yZD5Vbm5lY2Vzc2FyeSBQcm9j

ZWR1cmVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k

YXRlcz48ZGF0ZT5BcHIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNzU2LTE4

MzMgKEVsZWN0cm9uaWMpJiN4RDswOTU5LTgxMzggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjE4MzkwNDk2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9QTUMyMjkyMzM0L3BkZi9ibWot

MzM2LTc2NDgtcmVzLTAwODE2LWVsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMyMjkyMzM0PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2

L2Jtai4zOTUxOC40NjMyMDYuMjU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0

YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVu

ZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaW5uaW5nPC9BdXRob3I+PFllYXI+MjAwODwvWWVhcj48

UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PjE4MzkwNDk2PC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj40PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA2MTciPjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpbm5pbmcs

IEsuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuPC9hdXRob3I+PGF1dGhvcj5TdW1tZXJzLCBK

LjwvYXV0aG9yPjxhdXRob3I+TWFzc2V5LCBFLjwvYXV0aG9yPjxhdXRob3I+UG9vbGUsIEcuPC9h

dXRob3I+PGF1dGhvcj5EYW5pZWxzLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkludGVybmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9y

YXRvcnksIE5IUyBCbG9vZCBhbmQgVHJhbnNwbGFudCwgQnJpc3RvbCBCUzEwIDVORC48L2F1dGgt

YWRkcmVzcz48dGl0bGVzPjx0aXRsZT5FZmZlY3Qgb2YgaGlnaCB0aHJvdWdocHV0IFJIRCB0eXBp

bmcgb2YgZmV0YWwgRE5BIGluIG1hdGVybmFsIHBsYXNtYSBvbiB1c2Ugb2YgYW50aS1SaEQgaW1t

dW5vZ2xvYnVsaW4gaW4gUmhEIG5lZ2F0aXZlIHByZWduYW50IHdvbWVuOiBwcm9zcGVjdGl2ZSBm

ZWFzaWJpbGl0eSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5CTUo8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CTUo8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz44MTYtODwvcGFnZXM+PHZvbHVtZT4zMzY8L3ZvbHVtZT48bnVtYmVy

Pjc2NDg8L251bWJlcj48ZWRpdGlvbj4yMDA4LzA0LzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5

d29yZD5ETkEvIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8

L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIEJsb29kL2No

ZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEaXNlYXNlcy8gZ2VuZXRpY3M8L2tleXdv

cmQ+PGtleXdvcmQ+R2VuZXRpYyBUZWNobmlxdWVzL3N0YW5kYXJkczwva2V5d29yZD48a2V5d29y

ZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29y

ZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29y

ZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk

PlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNlbnNp

dGl2aXR5IGFuZCBTcGVjaWZpY2l0eTwva2V5d29yZD48a2V5d29yZD5Vbm5lY2Vzc2FyeSBQcm9j

ZWR1cmVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k

YXRlcz48ZGF0ZT5BcHIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNzU2LTE4

MzMgKEVsZWN0cm9uaWMpJiN4RDswOTU5LTgxMzggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjE4MzkwNDk2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9QTUMyMjkyMzM0L3BkZi9ibWot

MzM2LTc2NDgtcmVzLTAwODE2LWVsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMyMjkyMzM0PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2

L2Jtai4zOTUxOC40NjMyMDYuMjU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0

YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVu

ZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 17 Based on these figures and the number of births in Australia in 2016 the number of RhD-negative pregnant women and unnecessary anti-D treatments have been calculated as per REF _Ref481142815 \h \* MERGEFORMAT Table 1.Table SEQ Table \* ARABIC 1 Estimated number of women who would be tested and estimated number of women receiving unnecessary anti-D (annually) based on 2016 ABS dataTotal number of births 2016Estimated number of RhD negative pregnant women (women who would be tested)aEstimated number of women receiving unnecessary anti-D in the absence of NIPT (RhD-negative fetus)b311,10452,88721,155a 17% of total number of birthsb 40% of pregnancies in RhD negative womenSpecify any characteristics of patients with the medical condition, or suspected of, who would be eligible for the proposed medical service, including any details of how a patient would be investigated, managed and referred within the Australian health care system in the lead up to being considered eligible for the service:All pregnant women should undergo serological testing to ascertain their RhD status (positive or negative) in early pregnancy. RhD-negative women should also be tested for the presence of anti-D antibodies regardless if they have been known to be sensitised. ADDIN EN.CITE <EndNote><Cite><Author>RANZCOG</Author><Year>2015</Year><RecNum>25</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533105490">25</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>RANZCOG</author></authors></contributors><titles><title>Guidelines for the use of Rh(D) Immunoglobulin (Anti-D) in obstetrics in Australia</title></titles><volume>2018</volume><number>1st August</number><dates><year>2015</year></dates><publisher>The Royal Australian and New Zealand College of Obstetricians and Gynaecologists</publisher><urls><related-urls><url> As described above (Q24), all pregnant RhD-negative women should undergo non-invasive RhD testing to ascertain the RhD status of their fetus instead of receiving non-targeted anti-D prophylaxis. Define and summarise the current clinical management pathway before patients would be eligible for the proposed medical service (supplement this summary with an easy to follow flowchart [as an attachment to the Application Form] depicting the current clinical management pathway up to this point):As abovePART 6b – INFORMATION ABOUT THE INTERVENTIONDescribe the key components and clinical steps involved in delivering the proposed medical service:RhD-NIPT is used to detect fetal RhD DNA circulating in maternal blood. Initial observations found that cffDNA was present at about 1–10% of the concentration of maternal DNA in maternal plasma ADDIN EN.CITE <EndNote><Cite><Author>de Haas</Author><Year>2014</Year><RecNum>23</RecNum><IDText>25121157</IDText><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533103978">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>de Haas, M.</author><author>Finning, K.</author><author>Massey, E.</author><author>Roberts, D. J.</author></authors></contributors><titles><title>Anti-D prophylaxis: past, present and future</title><secondary-title>Transfus Med</secondary-title></titles><periodical><full-title>Transfus Med</full-title></periodical><pages>1-7</pages><volume>24</volume><number>1</number><edition>2014/08/15</edition><keywords><keyword>Antibodies, Monoclonal/ therapeutic use</keyword><keyword>Blood Grouping and Crossmatching/ methods</keyword><keyword>Clinical Trials as Topic</keyword><keyword>Erythroblastosis, Fetal/ prevention & control</keyword><keyword>Europe</keyword><keyword>Female</keyword><keyword>Genotype</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Pregnancy</keyword><keyword>Rh-Hr Blood-Group System</keyword><keyword>Rho(D) Immune Globulin/ therapeutic use</keyword></keywords><dates><year>2014</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1365-3148 (Electronic)0958-7578 (Linking)</isbn><accession-num>25121157</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>18 The test requires a venepuncture to be performed on the pregnant woman for the collection of a blood sample that is referred to a pathology laboratory for genetic analysis.High-throughput RhD NIPT is carried out using 4 ml to 6 ml of maternal anti-coagulated blood. DNA is extracted and amplified using real-time quantitative PCR. Primers and probes of the RHD gene are used, and the following controls are tested alongside the samples: RHD positive DNA; RHD negative DNA; RHD pseudogene positive DNA; and no DNA. The time to complete the test from sample receipt to report generation is 5 to 6 hours. ADDIN EN.CITE <EndNote><Cite><Author>NICE</Author><Year>2016</Year><RecNum>62</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534918813">62</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>NICE</author></authors></contributors><titles><title>High-throughput non-inHigh-throughput non-invasive prenatal testing for fetal RHD genotype: Diagnostics guidance</title></titles><volume>2018</volume><number>22nd August</number><dates><year>2016</year></dates><pub-location>London</pub-location><publisher>National Institute for Health and Care Excellence</publisher><urls><related-urls><url> should be offered to RhD-negative pregnant women prior to 28 weeks gestation, when prophylactic anti-D would normally be administered. The diagnostic accuracy of RhD-NIPT may vary according to different gestational ages at the time of sampling. Two meta-analyses found that the diagnostic accuracy of RhD-NIPT was higher in the first trimester than in the second and third trimester. However, a recent UK cohort study found that fetal RhD genotyping was more accurate for the prediction of RhD status if it was performed after, rather than before, 11 weeks’ gestation. ADDIN EN.CITE <EndNote><Cite><Author>Saramago</Author><Year>2018</Year><RecNum>3</RecNum><IDText>29580376</IDText><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533100529">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Saramago, P.</author><author>Yang, H.</author><author>Llewellyn, A.</author><author>Walker, R.</author><author>Harden, M.</author><author>Palmer, S.</author><author>Griffin, S.</author><author>Simmonds, M.</author></authors></contributors><auth-address>Centre for Health Economics, University of York, York, UK.Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.Centre for Reviews and Dissemination, University of York, York, UK.</auth-address><titles><title>High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation</title><secondary-title>Health Technol Assess</secondary-title></titles><periodical><full-title>Health Technol Assess</full-title></periodical><pages>1-172</pages><volume>22</volume><number>13</number><edition>2018/03/28</edition><dates><year>2018</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>2046-4924 (Electronic)1366-5278 (Linking)</isbn><accession-num>29580376</accession-num><urls></urls><custom2>PMC5890172</custom2><electronic-resource-num>10.3310/hta22130</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>3The RhD-NIPT result would be reported to the treating medical practitioner/obstetrician who would advise the patient of the result and whether or not anti-D should be administered.Does the proposed medical service include a registered trademark component with characteristics that distinguishes it from other similar health components?Various assays are available for NIPT using the same scientific principles and no single commercial or trademark product is endorsed in this application.If the proposed medical service has a prosthesis or device component to it, does it involve a new approach towards managing a particular sub-group of the population with the specific medical condition?N/AIf applicable, are there any limitations on the provision of the proposed medical service delivered to the patient (i.e. accessibility, dosage, quantity, duration or frequency):Once off diagnostic test for each pregnancy of a RhD-negative woman with the possibility of repeat testing in some instances where results are inconclusive, however women with an inconclusive result are usually treated as if positive and are administered anti-D.If applicable, identify any healthcare resources or other medical services that would need to be delivered at the same time as the proposed medical service:NoneIf applicable, advise which health professionals will primarily deliver the proposed service:Testing would be provided by Approved Practising Pathologists in line with other tests in the MBS Pathology Table.If applicable, advise whether the proposed medical service could be delegated or referred to another professional for delivery:The Australian Red Cross Blood Service currently provide this service.If applicable, specify any proposed limitations on who might deliver the proposed medical service, or who might provide a referral for it:N/AIf applicable, advise what type of training or qualifications would be required to perform the proposed service as well as any accreditation requirements to support service delivery:Testing would be delivered only by Approved Practising Pathologists in Accredited Pathology Laboratories (as defined in MBS Pathology table) by referral only by registered Medical Practitioners (non-pathologists) in line with other tests in the MBS Pathology Table.All RhD-negative pregnant women should be referred for RhD-NIPT by either their treating general practitioner or obstetrician.(a) Indicate the proposed setting(s) in which the proposed medical service will be delivered (select all relevant settings): FORMCHECKBOX Inpatient private hospital FORMCHECKBOX Inpatient public hospital FORMCHECKBOX Outpatient clinic FORMCHECKBOX Emergency Department FORMCHECKBOX Consulting rooms FORMCHECKBOX Day surgery centre FORMCHECKBOX Residential aged care facility FORMCHECKBOX Patient’s home FORMCHECKBOX Laboratory FORMCHECKBOX Other – please specify belowWhere the proposed medical service is provided in more than one setting, please describe the rationale related to each:N/AIs the proposed medical service intended to be entirely rendered in Australia? FORMCHECKBOX Yes FORMCHECKBOX No – please specify belowPART 6c – INFORMATION ABOUT THE COMPARATOR(S)Nominate the appropriate comparator(s) for the proposed medical service, i.e. how is the proposed population currently managed in the absence of the proposed medical service being available in the Australian health care system (including identifying health care resources that are needed to be delivered at the same time as the comparator service):There is no true diagnostic comparator test administered at the same point of time in the care pathway. All pregnant women will have their Rhesus D status determined by a standard antibody test. If found to be RhD negative, they will be administered universal anti-D prophylaxis without the determination of the RhD status of the fetus. The Rhesus D status of the fetus can only be determined by cord blood sampling after the birth of the baby, or the invasive options of amniocentesis or chorionic villus sampling, which have the potential for adverse events. It is rare for these procedures to be conducted – usually for reasons other than determining RhD status. In the year July 2017 to June 2018, there were a total of 4,079 services performed using MBS item numbers 16606, 16600, and 16603. This represents 1.3% of all live births during the same period (311,104). NIPT enables the targeted administration of anti-D only to RhD negative women who need it, preventing the needless administration of anti-D to RhD-negative women carrying an RhD-negative fetus.Does the medical service that has been nominated as the comparator have an existing MBS item number(s)? FORMCHECKBOX Yes (please provide all relevant MBS item numbers below) FORMCHECKBOX NoItem number 16606: Fetal blood sampling, using interventional techniques from umbilical cord or fetus, including fetal neuromuscular blockade and amniocentesis (Anaes.). Fee: $243.25Item number 16600: AMNIOCENTESIS, diagnostic. Fee: $63.50Item number 16603: CHORIONIC VILLUS SAMPLING, by any route. Fee: $121.85 Item number 65096: Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:(a) Identification and quantitation of any antibodies detected; and (b) (if performed) any test described in item 65060 or 65070. Fee: $41.00 Item number 65090: Blood grouping (including back-grouping if performed) - ABO and Rh (D antigen). Fee: $11.15Item number 65093: Blood grouping - Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system - 1 or more systems, including item 65090 (if performed). Fee: $22.00 Define and summarise the current clinical management pathways that patients may follow after they receive the medical service that has been nominated as the comparator (supplement this summary with an easy to follow flowchart [as an attachment to the Application Form] depicting the current clinical management pathway that patients may follow from the point of receiving the comparator onwards including health care resources):According to current clinical practice guidelines, all pregnant women found to be RhD negative by a standard antibody test should be offered anti-D prophylaxis at approximately 28 week’s gestation and again at around 34 weeks gestation. Universal anti-D prophylaxis is administered without the knowledge of the RhD status of the fetus. Rh (D) Immunoglobulin should not, however, be given to women: ? with preformed anti-D antibodies (alloimmunisation), except where the preformed antibodies are due to antenatal administration of Rh (D) Immunoglobulin;? who are Rh (D) positive;? who are Immunoglobulin A deficient, unless they have been tested and shown not to have circulating anti-IgA antibodies;? with a history of anaphylactic or other severe systemic reaction to Immunoglobulins.For women with severe thrombocytopenia or a coagulation disorder that contraindicates intramuscular injection, the intravenous preparation of Rh (D) Immunoglobulin should be used. ADDIN EN.CITE <EndNote><Cite><Author>NSW Health</Author><Year>2015</Year><RecNum>53</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534311397">53</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>NSW Health,</author></authors></contributors><titles><title>Guideline: Maternity - Rh (D) Immunoglobulin (Anti D)</title></titles><dates><year>2015</year></dates><pub-location>Sydney</pub-location><publisher>NSW Ministry of Health</publisher><urls><related-urls><url> National Blood Authority currently supplies RhD immunoglobulin, which is manufactured by CSL Behring, Australia.Figure SEQ Figure \* ARABIC 1Current care pathway for determining the RhD status in pregnant women ADDIN EN.CITE <EndNote><Cite><Author>NSW Health</Author><Year>2015</Year><RecNum>53</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534311397">53</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>NSW Health,</author></authors></contributors><titles><title>Guideline: Maternity - Rh (D) Immunoglobulin (Anti D)</title></titles><dates><year>2015</year></dates><pub-location>Sydney</pub-location><publisher>NSW Ministry of Health</publisher><urls><related-urls><url>(a) Will the proposed medical service be used in addition to, or instead of, the nominated comparator(s)? FORMCHECKBOX in addition to FORMCHECKBOX instead ofIf instead of, please outline the extent of which the current service/comparator is expected to be substituted:Rhesus D NIPT will only be offered to RhD-negative women, with anti-D prophylaxis only offered to RhD women carrying an RhD-positive fetus.Define and summarise how current clinical management pathways (from the point of service delivery onwards) are expected to change as a consequence of introducing the proposed medical service including variation in health care resources (Refer to Question 39 as baseline):The main difference in the care pathway of pregnant women who undergo RhD NIPT is the avoidance of the unnecessary administration of RhD immunoglobulin in women carrying an RhD negative fetus. Figure SEQ Figure \* ARABIC 2Care pathway for pregnant women with fetal RhD status determined by NIPTPART 6d – INFORMATION ABOUT THE CLINICAL OUTCOMESummarise the clinical claims for the proposed medical service against the appropriate comparator(s), in terms of consequences for health outcomes (comparative benefits and harms):When using the comparator, cord blood testing, the Rhesus D status of a fetus can only be determined after birth. As a consequence, anti-D prophylaxis is administered universally. It is ethically unacceptable to continue routine anti-D prophylaxis when fetal RHD genotyping using maternal blood is available and could identify those women who do not need this product. ADDIN EN.CITE <EndNote><Cite><Author>Johnson</Author><Year>2017</Year><RecNum>29</RecNum><IDText>28454757</IDText><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533106330">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Johnson, J. A.</author><author>MacDonald, K.</author><author>Clarke, G.</author><author>Skoll, A.</author></authors></contributors><auth-address>Calgary, AB.Vancouver, BC.Edmonton, AB.</auth-address><titles><title>No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here</title><secondary-title>J Obstet Gynaecol Can</secondary-title></titles><periodical><full-title>J Obstet Gynaecol Can</full-title></periodical><pages>366-373</pages><volume>39</volume><number>5</number><edition>2017/04/30</edition><dates><year>2017</year><pub-dates><date>May</date></pub-dates></dates><isbn>1701-2163 (Print)1701-2163 (Linking)</isbn><accession-num>28454757</accession-num><urls></urls><electronic-resource-num>10.1016/j.jogc.2016.12.006</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>21 Women should be aware and appropriately informed of all the risks and benefits of treatment with anti-D. In Australia, anti-D is manufactured from plasma collected from a small pool (less than 200) of RhD negative male plasma donors, who are injected with RhD-positive red blood cells to stimulate sensitisation and antibody production. Blood products prepared from multiple donors carry the risk of infection, and although the theoretical risk of transmission of viruses and prions is small, it is a risk that may be avoided if anti-D is only used when indicated. ADDIN EN.CITE <EndNote><Cite><Author>Johnson</Author><Year>2017</Year><RecNum>29</RecNum><IDText>28454757</IDText><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533106330">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Johnson, J. A.</author><author>MacDonald, K.</author><author>Clarke, G.</author><author>Skoll, A.</author></authors></contributors><auth-address>Calgary, AB.Vancouver, BC.Edmonton, AB.</auth-address><titles><title>No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here</title><secondary-title>J Obstet Gynaecol Can</secondary-title></titles><periodical><full-title>J Obstet Gynaecol Can</full-title></periodical><pages>366-373</pages><volume>39</volume><number>5</number><edition>2017/04/30</edition><dates><year>2017</year><pub-dates><date>May</date></pub-dates></dates><isbn>1701-2163 (Print)1701-2163 (Linking)</isbn><accession-num>28454757</accession-num><urls></urls><electronic-resource-num>10.1016/j.jogc.2016.12.006</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>21 The Australian Red Cross Blood Service estimates that approximately 17% of Australian women who become pregnant are RhD-negative and would receive routine anti-D prophylaxis.5 However, of all RhD-negative pregnant women, approximately 40 per cent will be carrying a RhD-negative fetus and would receive unnecessary anti-D prophylaxis.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaW5uaW5nPC9BdXRob3I+PFllYXI+MjAwODwvWWVhcj48

UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PjE4MzkwNDk2PC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj40PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA2MTciPjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpbm5pbmcs

IEsuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuPC9hdXRob3I+PGF1dGhvcj5TdW1tZXJzLCBK

LjwvYXV0aG9yPjxhdXRob3I+TWFzc2V5LCBFLjwvYXV0aG9yPjxhdXRob3I+UG9vbGUsIEcuPC9h

dXRob3I+PGF1dGhvcj5EYW5pZWxzLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkludGVybmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9y

YXRvcnksIE5IUyBCbG9vZCBhbmQgVHJhbnNwbGFudCwgQnJpc3RvbCBCUzEwIDVORC48L2F1dGgt

YWRkcmVzcz48dGl0bGVzPjx0aXRsZT5FZmZlY3Qgb2YgaGlnaCB0aHJvdWdocHV0IFJIRCB0eXBp

bmcgb2YgZmV0YWwgRE5BIGluIG1hdGVybmFsIHBsYXNtYSBvbiB1c2Ugb2YgYW50aS1SaEQgaW1t

dW5vZ2xvYnVsaW4gaW4gUmhEIG5lZ2F0aXZlIHByZWduYW50IHdvbWVuOiBwcm9zcGVjdGl2ZSBm

ZWFzaWJpbGl0eSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5CTUo8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CTUo8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz44MTYtODwvcGFnZXM+PHZvbHVtZT4zMzY8L3ZvbHVtZT48bnVtYmVy

Pjc2NDg8L251bWJlcj48ZWRpdGlvbj4yMDA4LzA0LzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5

d29yZD5ETkEvIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8

L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIEJsb29kL2No

ZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEaXNlYXNlcy8gZ2VuZXRpY3M8L2tleXdv

cmQ+PGtleXdvcmQ+R2VuZXRpYyBUZWNobmlxdWVzL3N0YW5kYXJkczwva2V5d29yZD48a2V5d29y

ZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29y

ZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29y

ZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk

PlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNlbnNp

dGl2aXR5IGFuZCBTcGVjaWZpY2l0eTwva2V5d29yZD48a2V5d29yZD5Vbm5lY2Vzc2FyeSBQcm9j

ZWR1cmVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k

YXRlcz48ZGF0ZT5BcHIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNzU2LTE4

MzMgKEVsZWN0cm9uaWMpJiN4RDswOTU5LTgxMzggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjE4MzkwNDk2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9QTUMyMjkyMzM0L3BkZi9ibWot

MzM2LTc2NDgtcmVzLTAwODE2LWVsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMyMjkyMzM0PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2

L2Jtai4zOTUxOC40NjMyMDYuMjU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0

YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVu

ZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaW5uaW5nPC9BdXRob3I+PFllYXI+MjAwODwvWWVhcj48

UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PjE4MzkwNDk2PC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj40PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA2MTciPjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpbm5pbmcs

IEsuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuPC9hdXRob3I+PGF1dGhvcj5TdW1tZXJzLCBK

LjwvYXV0aG9yPjxhdXRob3I+TWFzc2V5LCBFLjwvYXV0aG9yPjxhdXRob3I+UG9vbGUsIEcuPC9h

dXRob3I+PGF1dGhvcj5EYW5pZWxzLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkludGVybmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9y

YXRvcnksIE5IUyBCbG9vZCBhbmQgVHJhbnNwbGFudCwgQnJpc3RvbCBCUzEwIDVORC48L2F1dGgt

YWRkcmVzcz48dGl0bGVzPjx0aXRsZT5FZmZlY3Qgb2YgaGlnaCB0aHJvdWdocHV0IFJIRCB0eXBp

bmcgb2YgZmV0YWwgRE5BIGluIG1hdGVybmFsIHBsYXNtYSBvbiB1c2Ugb2YgYW50aS1SaEQgaW1t

dW5vZ2xvYnVsaW4gaW4gUmhEIG5lZ2F0aXZlIHByZWduYW50IHdvbWVuOiBwcm9zcGVjdGl2ZSBm

ZWFzaWJpbGl0eSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5CTUo8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CTUo8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz44MTYtODwvcGFnZXM+PHZvbHVtZT4zMzY8L3ZvbHVtZT48bnVtYmVy

Pjc2NDg8L251bWJlcj48ZWRpdGlvbj4yMDA4LzA0LzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5

d29yZD5ETkEvIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8

L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIEJsb29kL2No

ZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEaXNlYXNlcy8gZ2VuZXRpY3M8L2tleXdv

cmQ+PGtleXdvcmQ+R2VuZXRpYyBUZWNobmlxdWVzL3N0YW5kYXJkczwva2V5d29yZD48a2V5d29y

ZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29y

ZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29y

ZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk

PlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNlbnNp

dGl2aXR5IGFuZCBTcGVjaWZpY2l0eTwva2V5d29yZD48a2V5d29yZD5Vbm5lY2Vzc2FyeSBQcm9j

ZWR1cmVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k

YXRlcz48ZGF0ZT5BcHIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNzU2LTE4

MzMgKEVsZWN0cm9uaWMpJiN4RDswOTU5LTgxMzggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjE4MzkwNDk2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9QTUMyMjkyMzM0L3BkZi9ibWot

MzM2LTc2NDgtcmVzLTAwODE2LWVsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMyMjkyMzM0PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2

L2Jtai4zOTUxOC40NjMyMDYuMjU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0

YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVu

ZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 17 If RHD NIPT was offered to all RhD negative pregnant women it would assist them to make an informed choice about whether or not to have antenatal anti-D.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LZW50PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj

TnVtPjI3PC9SZWNOdW0+PElEVGV4dD4yNDU2ODU3MTwvSURUZXh0PjxEaXNwbGF5VGV4dD48c3R5

bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjIyPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJl

Yy1udW1iZXI+Mjc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk

PSJycHYyMGFkYWU5dHNkNmVhczBkcDkwc3d4ZHR2MGEyOXMyMHMiIHRpbWVzdGFtcD0iMTUzMzEw

NTkzOSI+Mjc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPktlbnQsIEou

PC9hdXRob3I+PGF1dGhvcj5GYXJyZWxsLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+U29vdGhpbGws

IFAuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0

bWVudCBvZiBIZWFsdGggJmFtcDsgU29jaWFsIFNjaWVuY2VzLCBVbml2ZXJzaXR5IG9mIHRoZSBX

ZXN0IG9mIEVuZ2xhbmQsIENvbGRoYXJib3VyIExhbmUsIEJyaXN0b2wgQlMxNiAxUVksIFVLLiBK

dWxpZS5LZW50QHV3ZS5hYy51ay48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Sb3V0aW5l

IGFkbWluaXN0cmF0aW9uIG9mIEFudGktRDogdGhlIGV0aGljYWwgY2FzZSBmb3Igb2ZmZXJpbmcg

cHJlZ25hbnQgd29tZW4gZmV0YWwgUkhEIGdlbm90eXBpbmcgYW5kIGEgcmV2aWV3IG9mIHBvbGlj

eSBhbmQgcHJhY3RpY2U8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+Qk1DIFByZWduYW5jeSBDaGls

ZGJpcnRoPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

Qk1DIFByZWduYW5jeSBDaGlsZGJpcnRoPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+

ODc8L3BhZ2VzPjx2b2x1bWU+MTQ8L3ZvbHVtZT48ZWRpdGlvbj4yMDE0LzAyLzI3PC9lZGl0aW9u

PjxrZXl3b3Jkcz48a2V5d29yZD5BbmVtaWEsIEhlbW9seXRpYy9kaWFnbm9zaXMvaW1tdW5vbG9n

eS9wcmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+RE5BL2dlbmV0aWNz

PC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBCbG9vZC8g

aW1tdW5vbG9neTwva2V5d29yZD48a2V5d29yZD5GZXR1cy8gaW1tdW5vbG9neTwva2V5d29yZD48

a2V5d29yZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdv

cmQ+SW5qZWN0aW9ucywgSW50cmF2ZW5vdXM8L2tleXdvcmQ+PGtleXdvcmQ+SXNvYW50aWJvZGll

cy8gYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3JkPlByYWN0aWNl

IEd1aWRlbGluZXMgYXMgVG9waWM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3Jk

PjxrZXl3b3JkPlByZW5hdGFsIERpYWdub3Npcy8gbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5S

aCBJc29pbW11bml6YXRpb24vIGJsb29kPC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdy

b3VwIFN5c3RlbS8gZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+UmhvKEQpIEltbXVuZSBHbG9i

dWxpbjwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjxwdWItZGF0

ZXM+PGRhdGU+RmViIDI1PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ3MS0yMzkz

IChFbGVjdHJvbmljKSYjeEQ7MTQ3MS0yMzkzIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51

bT4yNDU2ODU3MTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6

Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wbWMvYXJ0aWNsZXMvUE1DMzk0NDQzNi9wZGYvMTQ3MS0y

MzkzLTE0LTg3LnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUMzOTQ0

NDM2PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTg2LzE0NzEtMjM5My0x

NC04NzwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5O

TE08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3Jl

Y29yZD48L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LZW50PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj

TnVtPjI3PC9SZWNOdW0+PElEVGV4dD4yNDU2ODU3MTwvSURUZXh0PjxEaXNwbGF5VGV4dD48c3R5

bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjIyPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJl

Yy1udW1iZXI+Mjc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk

PSJycHYyMGFkYWU5dHNkNmVhczBkcDkwc3d4ZHR2MGEyOXMyMHMiIHRpbWVzdGFtcD0iMTUzMzEw

NTkzOSI+Mjc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPktlbnQsIEou

PC9hdXRob3I+PGF1dGhvcj5GYXJyZWxsLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+U29vdGhpbGws

IFAuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0

bWVudCBvZiBIZWFsdGggJmFtcDsgU29jaWFsIFNjaWVuY2VzLCBVbml2ZXJzaXR5IG9mIHRoZSBX

ZXN0IG9mIEVuZ2xhbmQsIENvbGRoYXJib3VyIExhbmUsIEJyaXN0b2wgQlMxNiAxUVksIFVLLiBK

dWxpZS5LZW50QHV3ZS5hYy51ay48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Sb3V0aW5l

IGFkbWluaXN0cmF0aW9uIG9mIEFudGktRDogdGhlIGV0aGljYWwgY2FzZSBmb3Igb2ZmZXJpbmcg

cHJlZ25hbnQgd29tZW4gZmV0YWwgUkhEIGdlbm90eXBpbmcgYW5kIGEgcmV2aWV3IG9mIHBvbGlj

eSBhbmQgcHJhY3RpY2U8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+Qk1DIFByZWduYW5jeSBDaGls

ZGJpcnRoPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

Qk1DIFByZWduYW5jeSBDaGlsZGJpcnRoPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+

ODc8L3BhZ2VzPjx2b2x1bWU+MTQ8L3ZvbHVtZT48ZWRpdGlvbj4yMDE0LzAyLzI3PC9lZGl0aW9u

PjxrZXl3b3Jkcz48a2V5d29yZD5BbmVtaWEsIEhlbW9seXRpYy9kaWFnbm9zaXMvaW1tdW5vbG9n

eS9wcmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+RE5BL2dlbmV0aWNz

PC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBCbG9vZC8g

aW1tdW5vbG9neTwva2V5d29yZD48a2V5d29yZD5GZXR1cy8gaW1tdW5vbG9neTwva2V5d29yZD48

a2V5d29yZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdv

cmQ+SW5qZWN0aW9ucywgSW50cmF2ZW5vdXM8L2tleXdvcmQ+PGtleXdvcmQ+SXNvYW50aWJvZGll

cy8gYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3JkPlByYWN0aWNl

IEd1aWRlbGluZXMgYXMgVG9waWM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3Jk

PjxrZXl3b3JkPlByZW5hdGFsIERpYWdub3Npcy8gbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5S

aCBJc29pbW11bml6YXRpb24vIGJsb29kPC9rZXl3b3JkPjxrZXl3b3JkPlJoLUhyIEJsb29kLUdy

b3VwIFN5c3RlbS8gZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+UmhvKEQpIEltbXVuZSBHbG9i

dWxpbjwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjxwdWItZGF0

ZXM+PGRhdGU+RmViIDI1PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ3MS0yMzkz

IChFbGVjdHJvbmljKSYjeEQ7MTQ3MS0yMzkzIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51

bT4yNDU2ODU3MTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6

Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wbWMvYXJ0aWNsZXMvUE1DMzk0NDQzNi9wZGYvMTQ3MS0y

MzkzLTE0LTg3LnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUMzOTQ0

NDM2PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTg2LzE0NzEtMjM5My0x

NC04NzwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5O

TE08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3Jl

Y29yZD48L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE.DATA 22In addition, the domestic supply of anti-D is threatened due to an ageing donor population, gradual decline in people available with anti-D antibodies. Australia is almost self-sufficient in the supply of anti-D, with the majority manufactured by CSL Behring, however, it has been necessary to import some product to meet demand, making supply vulnerable due to a world-wide shortage of anti-D.Please advise if the overall clinical claim is for: FORMCHECKBOX Superiority FORMCHECKBOX Non-inferiorityBelow, list the key health outcomes (major and minor – prioritising major key health outcomes first) that will need to be specifically measured in assessing the clinical claim of the proposed medical service versus the comparator:Safety Outcomes: Sensitisation eventsRate of fetal adverse events including fetal anaemia and fetal heart failure, oedema, hydrops fetalis, neonatal jaundice and mortality.Clinical Effectiveness Outcomes: Assessment of diagnostic/test accuracy: sensitivity, specificity, number of false positives, number of false negatives, number of inconclusive resultsAssessment of clinical outcomesCost-effectivenessReduction in the administration of anti-DPART 7 – INFORMATION ABOUT ESTIMATED UTILISATIONEstimate the prevalence and/or incidence of the proposed population:The Australian Red Cross Blood Service estimates that approximately 17% of Australian women who become pregnant are RhD-negative and would receive routine anti-D prophylaxis. However, of all RhD-negative pregnant women, approximately 40 per cent will be carrying an RhD-negative fetus and would receive unnecessary anti-D prophylaxis.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaW5uaW5nPC9BdXRob3I+PFllYXI+MjAwODwvWWVhcj48

UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PjE4MzkwNDk2PC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj40PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA2MTciPjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpbm5pbmcs

IEsuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuPC9hdXRob3I+PGF1dGhvcj5TdW1tZXJzLCBK

LjwvYXV0aG9yPjxhdXRob3I+TWFzc2V5LCBFLjwvYXV0aG9yPjxhdXRob3I+UG9vbGUsIEcuPC9h

dXRob3I+PGF1dGhvcj5EYW5pZWxzLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkludGVybmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9y

YXRvcnksIE5IUyBCbG9vZCBhbmQgVHJhbnNwbGFudCwgQnJpc3RvbCBCUzEwIDVORC48L2F1dGgt

YWRkcmVzcz48dGl0bGVzPjx0aXRsZT5FZmZlY3Qgb2YgaGlnaCB0aHJvdWdocHV0IFJIRCB0eXBp

bmcgb2YgZmV0YWwgRE5BIGluIG1hdGVybmFsIHBsYXNtYSBvbiB1c2Ugb2YgYW50aS1SaEQgaW1t

dW5vZ2xvYnVsaW4gaW4gUmhEIG5lZ2F0aXZlIHByZWduYW50IHdvbWVuOiBwcm9zcGVjdGl2ZSBm

ZWFzaWJpbGl0eSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5CTUo8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CTUo8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz44MTYtODwvcGFnZXM+PHZvbHVtZT4zMzY8L3ZvbHVtZT48bnVtYmVy

Pjc2NDg8L251bWJlcj48ZWRpdGlvbj4yMDA4LzA0LzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5

d29yZD5ETkEvIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8

L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIEJsb29kL2No

ZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEaXNlYXNlcy8gZ2VuZXRpY3M8L2tleXdv

cmQ+PGtleXdvcmQ+R2VuZXRpYyBUZWNobmlxdWVzL3N0YW5kYXJkczwva2V5d29yZD48a2V5d29y

ZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29y

ZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29y

ZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk

PlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNlbnNp

dGl2aXR5IGFuZCBTcGVjaWZpY2l0eTwva2V5d29yZD48a2V5d29yZD5Vbm5lY2Vzc2FyeSBQcm9j

ZWR1cmVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k

YXRlcz48ZGF0ZT5BcHIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNzU2LTE4

MzMgKEVsZWN0cm9uaWMpJiN4RDswOTU5LTgxMzggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjE4MzkwNDk2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9QTUMyMjkyMzM0L3BkZi9ibWot

MzM2LTc2NDgtcmVzLTAwODE2LWVsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMyMjkyMzM0PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2

L2Jtai4zOTUxOC40NjMyMDYuMjU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0

YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVu

ZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GaW5uaW5nPC9BdXRob3I+PFllYXI+MjAwODwvWWVhcj48

UmVjTnVtPjQ8L1JlY051bT48SURUZXh0PjE4MzkwNDk2PC9JRFRleHQ+PERpc3BsYXlUZXh0Pjxz

dHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+MTc8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj40PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0icnB2MjBhZGFlOXRzZDZlYXMwZHA5MHN3eGR0djBhMjlzMjBzIiB0aW1lc3RhbXA9IjE1MzMx

MDA2MTciPjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpbm5pbmcs

IEsuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIFAuPC9hdXRob3I+PGF1dGhvcj5TdW1tZXJzLCBK

LjwvYXV0aG9yPjxhdXRob3I+TWFzc2V5LCBFLjwvYXV0aG9yPjxhdXRob3I+UG9vbGUsIEcuPC9h

dXRob3I+PGF1dGhvcj5EYW5pZWxzLCBHLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkludGVybmF0aW9uYWwgQmxvb2QgR3JvdXAgUmVmZXJlbmNlIExhYm9y

YXRvcnksIE5IUyBCbG9vZCBhbmQgVHJhbnNwbGFudCwgQnJpc3RvbCBCUzEwIDVORC48L2F1dGgt

YWRkcmVzcz48dGl0bGVzPjx0aXRsZT5FZmZlY3Qgb2YgaGlnaCB0aHJvdWdocHV0IFJIRCB0eXBp

bmcgb2YgZmV0YWwgRE5BIGluIG1hdGVybmFsIHBsYXNtYSBvbiB1c2Ugb2YgYW50aS1SaEQgaW1t

dW5vZ2xvYnVsaW4gaW4gUmhEIG5lZ2F0aXZlIHByZWduYW50IHdvbWVuOiBwcm9zcGVjdGl2ZSBm

ZWFzaWJpbGl0eSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5CTUo8L3NlY29uZGFyeS10

aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CTUo8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz44MTYtODwvcGFnZXM+PHZvbHVtZT4zMzY8L3ZvbHVtZT48bnVtYmVy

Pjc2NDg8L251bWJlcj48ZWRpdGlvbj4yMDA4LzA0LzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5

d29yZD5ETkEvIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkZlYXNpYmlsaXR5IFN0dWRpZXM8

L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIEJsb29kL2No

ZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEaXNlYXNlcy8gZ2VuZXRpY3M8L2tleXdv

cmQ+PGtleXdvcmQ+R2VuZXRpYyBUZWNobmlxdWVzL3N0YW5kYXJkczwva2V5d29yZD48a2V5d29y

ZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29y

ZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29y

ZD48a2V5d29yZD5SaCBJc29pbW11bml6YXRpb24vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk

PlJobyhEKSBJbW11bmUgR2xvYnVsaW4vIGdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNlbnNp

dGl2aXR5IGFuZCBTcGVjaWZpY2l0eTwva2V5d29yZD48a2V5d29yZD5Vbm5lY2Vzc2FyeSBQcm9j

ZWR1cmVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k

YXRlcz48ZGF0ZT5BcHIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNzU2LTE4

MzMgKEVsZWN0cm9uaWMpJiN4RDswOTU5LTgxMzggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t

bnVtPjE4MzkwNDk2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw

czovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9QTUMyMjkyMzM0L3BkZi9ibWot

MzM2LTc2NDgtcmVzLTAwODE2LWVsLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMyMjkyMzM0PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2

L2Jtai4zOTUxOC40NjMyMDYuMjU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0

YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVu

ZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 17 Based on these figures and the number of births in Australia in 2016 the number of RhD-negative pregnant women and unnecessary anti-D treatments have been calculated as per REF _Ref525124535 \h \* MERGEFORMAT Table 2.Table SEQ Table \* ARABIC 2 Estimated number of women who would be tested and receive unnecessary anti-D, annually (based on 2016 ABS data)YearEstimated number of births each yearcEstimated number of RhD negative pregnant women who would be testedaEstimated number women receiving unnecessary anti-D in absence of NIPT (RhD-negative fetus)b2016311,10452,88721,1552017316, 92153,87621,5502018322, 84754,88421,9542019328, 88455,91022,3642020335, 03456,95622,7822021341, 29958,02123,208a 17% of total number of birthsb 40% of pregnancies in RhD negative womenc Estimates based on an increase in the number of births from 2015 to 2016 of 1.87%Estimate the number of times the proposed medical service(s) would be delivered to a patient per year:Rhesus D NIPT should be performed for every pregnancy of an RhD negative mother. How many years would the proposed medical service(s) be required for the patient?The number of tests performed will be based on the number of pregnancies per women – in 2016, Australia's total fertility rate was 1.79 babies per woman.Estimate the projected number of patients who will utilise the proposed medical service(s) for the first full year:The number of births increased by 1.87% from 2015 to 2016. Based on the number of births in 2016, it would be expected that approximately 55,910 RhD negative pregnant women should be tested in 2019 ( REF _Ref525124535 \h \* MERGEFORMAT Table 2).Estimate the anticipated uptake of the proposed medical service over the next three years factoring in any constraints in the health system in meeting the needs of the proposed population (such as supply and demand factors) as well as provide commentary on risk of ‘leakage’ to populations not targeted by the service:The estimated number of RhD negative pregnant women for 2019-2021 is summarised in REF _Ref525124535 \h \* MERGEFORMAT Table 2 (Question 46). PART 8 – COST INFORMATIONIndicate the likely cost of providing the proposed medical service. Where possible, please provide overall cost and breakdown:An Australian cost-effectiveness analysis was conducted by Gordon et al in 2017, and estimated that the mean cost per person for the RHD gene test was AU$45.48. This figure was based on the large-scale testing of 46,000 women – based on an RhD negative prevalence of 15 percent. The analysis took into account the physical space required by a laboratory to conduct the test, staffing requirements, ancillary equipment in addition to consumables used in the testing (including a discount for bulk purchase). The study took a health system perspective including direct costs incurred by hospitals, the National Blood Authority, and the Australian Red Cross Blood Service. ADDIN EN.CITE <EndNote><Cite><Author>Gordon</Author><Year>2017</Year><RecNum>15</RecNum><IDText>29096422</IDText><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533101424">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gordon, L. G.</author><author>Hyland, C. A.</author><author>Hyett, J. A.</author><author>O'Brien, H.</author><author>Millard, G.</author><author>Flower, R. L.</author><author>Gardener, G. J.</author></authors></contributors><auth-address>QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Australia.Queensland University of Technology, School of Nursing, Brisbane, Australia.Australian Red Cross Blood Service, Brisbane, Australia.Clinical Professor and Head of High Risk Obstetrics, RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, Australia.Centre for Maternal Fetal Medicine at Mater Mothers' Hospitals, Brisbane, Australia.</auth-address><titles><title>Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis</title><secondary-title>Prenat Diagn</secondary-title></titles><periodical><full-title>Prenat Diagn</full-title></periodical><pages>1245-1253</pages><volume>37</volume><number>12</number><edition>2017/11/03</edition><dates><year>2017</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1097-0223 (Electronic)0197-3851 (Linking)</isbn><accession-num>29096422</accession-num><urls><related-urls><url> The cost of the test would likely increase slightly from that quoted by Gordon et al if performed by several smaller laboratories.The results of the analysis found that the mean cost for a pregnancy in an RhD negative woman under universal anti‐D prophylaxis was $7,495 compared with 7,471 for NIPT, representing a small cost-saving per person to the health system. With NIPT, 13 938 women would avoid unnecessary antenatal anti‐D prophylaxis at a total cost savings to the National Blood Authority of $2.1 million per year. To the health system, net cost savings of $159,701 per year (0.05%) were predicted for total health care costs. ADDIN EN.CITE <EndNote><Cite><Author>Gordon</Author><Year>2017</Year><RecNum>15</RecNum><IDText>29096422</IDText><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533101424">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gordon, L. G.</author><author>Hyland, C. A.</author><author>Hyett, J. A.</author><author>O'Brien, H.</author><author>Millard, G.</author><author>Flower, R. L.</author><author>Gardener, G. J.</author></authors></contributors><auth-address>QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Australia.Queensland University of Technology, School of Nursing, Brisbane, Australia.Australian Red Cross Blood Service, Brisbane, Australia.Clinical Professor and Head of High Risk Obstetrics, RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, Australia.Centre for Maternal Fetal Medicine at Mater Mothers' Hospitals, Brisbane, Australia.</auth-address><titles><title>Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis</title><secondary-title>Prenat Diagn</secondary-title></titles><periodical><full-title>Prenat Diagn</full-title></periodical><pages>1245-1253</pages><volume>37</volume><number>12</number><edition>2017/11/03</edition><dates><year>2017</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1097-0223 (Electronic)0197-3851 (Linking)</isbn><accession-num>29096422</accession-num><urls><related-urls><url> A full summary of the costs of universal versus targeted anti-D prophylaxis can be found in REF _Ref525128790 \h Figure 3. The cost of RhD immunoglobulin in Australia in 2015 was $29.38 for 250 IU and $73.41 for 625 IU (manufactured by CSL Behring, Australia). In 2018, the National Blood Authority lists prices as follows:RhD immunoglobulin (plasma derived – imported) Rhophylac – 1500 IU = $411.22RhD immunoglobulin (Glycine Formulation, plasma derived - domestic) – 250 IU = $29.79, 625 IU = $74.44 ADDIN EN.CITE <EndNote><Cite><Author>NBA</Author><Year>2018</Year><RecNum>54</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534814751">54</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>NBA</author></authors></contributors><titles><title>What Blood Products are Supplied - National Product List</title></titles><volume>2018</volume><number>21st August</number><dates><year>2018</year></dates><pub-location>Canberra</pub-location><publisher>National Blood Authority Australia</publisher><urls><related-urls><url> is expected that RhD NIPT will deliver savings to the Australian health system from the reduction in the widespread and unnecessary use of anti-D, in addition to reducing the potential reliance on an overseas source for anti-D, which may be associated with risks such as infection.Specify how long the proposed medical service typically takes to perform:The time to complete the test from sample receipt to report generation is 5 to 6 hours. ADDIN EN.CITE <EndNote><Cite><Author>NICE</Author><Year>2016</Year><RecNum>62</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1534918813">62</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>NICE</author></authors></contributors><titles><title>High-throughput non-inHigh-throughput non-invasive prenatal testing for fetal RHD genotype: Diagnostics guidance</title></titles><volume>2018</volume><number>22nd August</number><dates><year>2016</year></dates><pub-location>London</pub-location><publisher>National Institute for Health and Care Excellence</publisher><urls><related-urls><url> public funding is sought through the MBS, please draft a proposed MBS item descriptor to define the population and medical service usage characteristics that would define eligibility for MBS funding.MBS Pathology Table Category 6, Group P7 -GeneticsProposed item descriptor: Non-invasive prenatal testing of blood from a Rhesus D negative pregnant woman for the detection of Rhesus D fetal DNA circulating in maternal blood.Fee: $XXXFigure SEQ Figure \* ARABIC 3Summary of economic analysis of universal versus targeted anti-D prophylaxis (annual) ADDIN EN.CITE <EndNote><Cite><Author>Gordon</Author><Year>2017</Year><RecNum>15</RecNum><IDText>29096422</IDText><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="rpv20adae9tsd6eas0dp90swxdtv0a29s20s" timestamp="1533101424">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gordon, L. G.</author><author>Hyland, C. A.</author><author>Hyett, J. A.</author><author>O'Brien, H.</author><author>Millard, G.</author><author>Flower, R. L.</author><author>Gardener, G. J.</author></authors></contributors><auth-address>QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Australia.Queensland University of Technology, School of Nursing, Brisbane, Australia.Australian Red Cross Blood Service, Brisbane, Australia.Clinical Professor and Head of High Risk Obstetrics, RPA Women and Babies, Royal Prince Alfred Hospital, Sydney, Australia.Centre for Maternal Fetal Medicine at Mater Mothers' Hospitals, Brisbane, Australia.</auth-address><titles><title>Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis</title><secondary-title>Prenat Diagn</secondary-title></titles><periodical><full-title>Prenat Diagn</full-title></periodical><pages>1245-1253</pages><volume>37</volume><number>12</number><edition>2017/11/03</edition><dates><year>2017</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1097-0223 (Electronic)0197-3851 (Linking)</isbn><accession-num>29096422</accession-num><urls><related-urls><url> 9 – FEEDBACKThe Department is interested in your feedback.How long did it take to complete the Application Form? FORMTEXT Insert approximate duration here(a) Was the Application Form clear and easy to complete? FORMCHECKBOX Yes FORMCHECKBOX NoIf no, provide areas of concern: FORMTEXT Describe areas of concern here(a) Are the associated Guidelines to the Application Form useful? FORMCHECKBOX Yes FORMCHECKBOX NoIf no, what areas did you find not to be useful? FORMTEXT Insert feedback here(a) Is there any information that the Department should consider in the future relating to the questions within the Application Form that is not contained in the Application Form? FORMCHECKBOX Yes FORMCHECKBOX NoIf yes, please advise:The question numbers in the template do not align with the question numbers in the GuideQuestion 41 does not make sense – you are asking 2 questions here and yet require a Yes or No answer. (a) Will the proposed medical service be used in addition to, or instead of, the nominated comparator(s)? FORMCHECKBOX Yes FORMCHECKBOX NoThe Questions needs to be (a) Will the proposed medical service be used in addition to, or instead of, the nominated comparator(s)? FORMCHECKBOX in addition to FORMCHECKBOX instead of Followed byIf instead of, please outline the extent of which the current service/comparator is expected to be substituted:Question 8 in Template/ Question 9 in Guideline Question 8 in the template (2.4) does NOT have choice iv – which the Guideline DOESvi. A service that tests for heritable mutations in clinically affected individuals to make a genetic diagnosis and thus estimate their variation in (predisposition for) future risk of further disease and, when also appropriate, cascade testing of family members of those individuals who test positive for one or more relevant mutations, to make a genetic diagnosis and thus estimate each family member’s variation in (predisposition for) future risk of developing the clinical disease.References ADDIN EN.REFLIST 1.Lyon, C. &English, A. (2018). 'PURL: A new protocol for RhD-negative pregnant women?'. J Fam Pract, 67 (5), 306;8;19.2.RANZCOG (2015). Guidelines for the use of Rh(D) Immunoglobulin (Anti-D) in obstetrics in Australia. [Internet]. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Available from: [Accessed 1st August 2018].3.Saramago, P., Yang, H.et al (2018). 'High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation'. Health Technol Assess, 22 (13), 1-172.4.Sorensen, K., Kjeldsen-Kragh, J.et al (2018). 'Determination of fetal RHD type in plasma of RhD negative pregnant women'. Scand J Clin Lab Invest, 1-6.5.Saramago, P., Yang, H.et al (2018). 'High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis'. BJOG.6.Manfroi, S., Calisesi, C.et al (2018). 'Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis'. Blood Transfus, 1-11.7.Clausen, F. B., Barrett, A. N.et al (2018). 'Non-invasive foetal RhD genotyping to guide anti-D prophylaxis: an external quality assurance workshop'. Blood Transfus, 16 (4), 359-62.8.Mackie, F. L., Hemming, K.et al (2017). 'The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis'. BJOG, 124 (1), 32-46.9.Haimila, K., Sulin, K.et al (2017). 'Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland'. Acta Obstet Gynecol Scand, 96 (10), 1228-33.10.Gordon, L. G., Hyland, C. A.et al (2017). 'Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: A cost-effectiveness analysis'. Prenat Diagn, 37 (12), 1245-53.11.Vivanti, A., Benachi, A.et al (2016). 'Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy'. Am J Obstet Gynecol, 215 (5), 606 e1- e5.12.Neovius, M., Tiblad, E.et al (2016). 'Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis'. BJOG, 123 (8), 1337-46.13.de Haas, M., Thurik, F. F.et al (2016). 'Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands'. BMJ, 355, i5789.14.Teitelbaum, L., Metcalfe, A.et al (2015). 'Costs and benefits of non-invasive fetal RhD determination'. Ultrasound Obstet Gynecol, 45 (1), 84-8.15.Soothill, P. W., Finning, K.et al (2015). 'Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS'. BJOG, 122 (12), 1682-6.16.Gandhi, A. (2016). Haemolytic Disease of the Fetus and Newborn. [Internet]. Patient Platform Ltd. Available from: [Accessed 1st August 2018].17.Finning, K., Martin, P.et al (2008). 'Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study'. BMJ, 336 (7648), 816-8.18.de Haas, M., Finning, K.et al (2014). 'Anti-D prophylaxis: past, present and future'. Transfus Med, 24 (1), 1-7.19.NICE (2016). High-throughput non-inHigh-throughput non-invasive prenatal testing for fetal RHD genotype: Diagnostics guidance. [Internet]. National Institute for Health and Care Excellence. Available from: [Accessed 22nd August 2018].20.NSW Health (2015). Guideline: Maternity - Rh (D) Immunoglobulin (Anti D), NSW Ministry of Health, Sydney , J. A., MacDonald, K.et al (2017). 'No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here'. J Obstet Gynaecol Can, 39 (5), 366-73.22.Kent, J., Farrell, A. M. &Soothill, P. (2014). 'Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice'. BMC Pregnancy Childbirth, 14, 87.23.NBA (2018). What Blood Products are Supplied - National Product List. [Internet]. National Blood Authority Australia. Available from: [Accessed 21st August 2018]. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

To fulfill the demand for quickly locating and searching documents.

It is intelligent file search solution for home and business.

Literature Lottery

To fulfill the demand for quickly locating and searching documents.

Related download

Related searches